CA2417635C - Heterocyclic compounds useful as inhibitors of tyrosine kinases - Google Patents

Abstract

Disclosed are novel compounds of formula (I) (see formula I as described in specification) wherein Ar1, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.

Description

HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE
KINASES
Field of the Invention This invention relates to substituted compounds of formula (I):
P.Q N
\~Y~Ar~
x Het (I) wherein Arl, X, Y, P, Q and Het are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the 2o treatment of various diseases, processes for preparing these compounds and intermediate useful in these processes.
Background of the Invention Tyrosine kinases play an essential role in the regulation of cell signaling and cell proliferation by phosphorylating tyrosine residues of peptides and proteins.
Inappropriate activation of tyrosine kinases is known to be involved in a variety of disease states, including immunologic and oncologic disorders.
It has been well established that T cells play an important role in regulating the immune response (F. Powrie and R.L. Coffinan, Imrnunol. Today, 1993,14, 270).
Activation of T
cells is often the initiating event in many inflammatory and autoimmune diseases. In addition to their role in immune surveillance, T cells can become autoreactive by recognizing self antigens and thereby cause autoimmune disease such as rheumatoid arthritis and inflammatory bowel disease.
to The T cell receptor (TCR) is the antigen-specific component of the T cell and is activated when the receptor is engaged with foreign or self antigenic peptides. When the TCR is activated a series of enzyme-mediated signal transduction cascades is initiated which results in the production of pro-inflammatory cytokines such as interlukin-2 (IL-2).
is The release of IL-2 is critically important since this lymphokine is required for T-lymphocyte proliferation, differentiation, and effector function. Clinical studies have shown that interference with IL-2 activity effectively suppresses immune response in vivo (T.A. Waldmann, Immunol. Today, 1993,14, 270). Accordingly, agents which inhibit T-lymphocyte activation and subsequent IL-2 production, or block the activity of IL-2 are 2o therapeutically useful for selectively suppressing immune response in a patient in need of such immunosuppression.
The eight members of the src family of tyrosine kinases are src, lck, fyn, lyn, hck, fgr, blk and yes (J.B. Bolen, J.S. Brugge, Ann. Rev. Immunol., 1997, I5, 371). These can be 2s divided into 2 groups based on their pattern of tissue expression. Src, fyn and yes have a broad distribution while expression of lck, lyn, hck, fgr, and blk is largely limited to hemopoietic cells. The therapeutic effects of inhibiting kinases of the src family can be ascertained by linking functional defects seen in gene disruption studies in mice. Src(-/-) mice had severe abnormalities in bone remodeling. Inhibition of src may therefore be 3o useful in treating osteoporosis. Lck(-/-) mice display a complete lack of CD4+ cells are unable to mount antigen-dependent immune responses.

A kinase of particular interest is p561ck, which is only expressed in T-cells.
Within the TCR signal transduction cascade the tyrosine kinase p561ck is a required element to initiate the activation response from the TCR intracellular domains to other signaling proteins. For example, T cells which lack the p561ck protein are unable to signal through the T cell receptor (D.B. Straus and A. Weiss, Cell, 1992, 70, 585). Transfection of p561ck back into these cell lines restores TCR responsiveness. Also, it has been shown in mice that inactivation of the p561ck gene leads to lack of proper thymocyte development (T.J.
Molina et al., Nature, 1992, 357, 161).
The conclusion drawn from these studies is that p561ck plays a crucial role in T cell maturation and antigen-induced T-cell activation. Therefore, an agent blocking p561ck would effectively block T cell function, act as an immunosuppressive agent and have potential utility in autoimmune diseases, for example rheumatoid arthritis, multiple sclerosis, lupus, transplant rejection and allergic diseases (J.H. Hanke et al., Inflamm. Res., 1995, 44, 357).
Inhibitors of other members of the src family of non-receptor tyrosine kinases are also useful for treating various disease states. Src is present in osteoclasts, and is important in 2o bone remodeling. For example, inactivation of p60src diminishes bone resorption by osteoclasts (P. Soriano et al., Cell 1991, 64, 693, B.F. Boyce et al. J. Clin.
Invest 1992, 90, 1622), it is therefore possible that inhibitors of the kinase activity of p60src are useful in the treatment of osteoporosis, Paget's disease and inflammation of bones and joints.
Src kinases have been found to be activated in tumors, including breast and colon cancers, melanoma and sarcoma. For example, a number of primary tumors and tumor cell lines from patients with breast cancer, colon cancer, melanoma and sarcoma have been shown to have elevated src kinase activity, and activating src mutations are seen in some advanced 3o colon cancers. Inhibitors of src kinase had significant antiproliferative activity against cancer cell lines (M.M. Moasser et al., Cancer Res., 1999, 59, 6145) and inhibited the transformation of cells to an oncogenic phenotype (R. Karni et al., Oncogene, 1999, 18, 4654) suggesting that src kinase inhibitors may be useful anti-cancer agents.
Src inhibitors have also been reported to be effective in an animal model of cerebral ischemia (R. Paul et al. Nature Medicine 2001, 7, 222), suggesting that src kinase inhibitors may thus be useful in treating conditions involving cerebral ischemia. For example, src kinase inhibitors may be useful in reducing brain damage following stroke.
In addition, src family kinases participate in signal transduction in several cell types. For to example, fyn, like lck, is involved in T-cell activation. Hck and fgr are involved in Fc gamma receptor mediated oxidative burst of neutrophils. Src and lyn are believed to be important in Fc epsilon induced degranulation of mast cells, and so may play a role in asthma and other allergic diseases. The kinase lyn is known to be involved in the cellular response to DNA damage induced by UV light (T. Hiwasa, FEBS Lett. 1999, 444, 173) or 15 ionizing radiation (S. Kumar, J. Biol Chern,1998, 273, 25654). Inhibitors of lyn kinase may thus be useful as potentiators in radiation therapy.
Platelet derived growth factor is a potent mitogen for smooth muscle cells.
Its receptor (PDGFR) is a member of the receptor tyrosine kinase family (L. Claesson-Welsh, J. Biol 2o Chem, 1994, 269, 32023). PDGF is involved in atherosclerosis and restenosis (K.E.
Bornfeldt, Tnends Cardiovasc. Med., 1996, 6, 143). In addition, receptor tyrosine kinases including PDGFR kinase have been implicated as contributing factors in cancer (A.
Levitzki and A. Gazit, Science, 1995, 267, 172) including ovarian (M.B. Dabrow et al., Gynecologic Oncology, 199, 71, 29) and prostate (S.M. Sintich et al., Endocrinology, 25 1999,140, 3411) cancers and glioblastoma (B.J. Silver, BioFactors, 1992 3, 217).
Inhibitors of PDGFR kinase are thus useful in the treatment of fibrotic diseases, restenosis and PDGF-dependent tumors.
Reports have appeared in the literature of agents that inhibit the kinase activity of p561ck 3o kinase and thus inhibit T cell activation. These include the natural product lavendustin A, and analogs (M.S. Smyth, J. Med. Chem., 1993, 36, 3010), the natural product damnacanthal (C.R. Faltynek et al., Biochemistry, 1995, 34, 12404), and a 1-methoxy agroclavine isolated from a fungal extract (R. Padmanabha et al. Bioorganic and Med.
Chem. Letters, 1998, 8, 569). Other inhibitors reported include WIN 61651 (J.
Enzyme Inhibition, 1995, 9, 111) pyrazolopyrimidines PP1 and PP2 (Hanke et al. J.
Biol Chem, 1996, 271, 695) and indanone and indandione derivatives (J.L. Bullington et al., Bioorganic and Med. Chem. Letters, 1998, 8, 2489).
A.P. Spader et al. (WO 98/54157, 1998) describe quinoline and quinoxaline compounds that inhibit p561ck and PDGFR kinase. Fused polycyclic 2-aminopyrimidine derivatives l0 that inhibit p561ck are reported by J.M. Davis et al. (WO 98128281, 1998).
J. Das et al.
claim a series of benzothiazole amides as inhibitors of lck and other src family kinases (WO 99/24035, 1999). Inhibitors of PDGFR kinase and src-family kinases were reviewed by H.D.H. Showalter, A.J. Kraker, Pharmacol. Ther., 1997, 76, 55. Several patents on inhibitors of lck are reviewed in P.M. Traxler, Exp. Opin. Ther. Patents, 1997, 7, 571,and P.M. Trailer, Exp. Opin. Ther. Patents, 1998, 8, 1599.
EP 322 746 A1 discloses heterocyclic lactam derivatives described as being useful as cardiotonic agents, antihypertensive agents and vasodilators.
2o Examples of tricyclic systems similar to formula (I) above are known, but not having the 2-amino substituents on the benzimidazole ring. See S. W. Schneller et al., J.
Med. Chem., 1989, 32, 2247. Examples of tricyclic systems similar to formula (I) with a carbamate at the 2-position have been reported in S. Kumar et al., Indian J. Chern. 1981, 20B, 1068 and S. Agarwal et al., Z. ~Vaturfof sch. C, 1993, 48, 829.
The compounds of the present invention represent a novel structural class, which is distinct from previously reported tyrosine kinase inhibitors.

Brief Summary of the Invention The work cited above supports the principle that inhibition of the kinases mentioned above will be beneficial in the treatment of various disease states.
It is therefore an object of the invention to provide novel compounds which inhibit PDGFR
kinase and the src-family kinases including lck, src, fyn, lyn, hck, fgr, blk and yes.
It is a further object of the invention to provide methods for treating diseases and 1o pathological conditions mediated by src-family tyrosine kinases and PDGFR
kinase such as autoimmune diseases, transplant rejection, psoriasis, osteoporosis, Paget's disease, cancer, including src-dependent tumors and PDGF-dependent tumors, cerebral ischemic conditions, atherosclerosis, restenosis and allergic diseases, using the novel compounds of the invention.
It is yet a further object of the invention to provide processes of preparation of the above-mentioned novel compounds and pharmaceutical compositions comprising the same.
Detailed Description of the Invention The src-family tyrosine kinases and PDGFR kinase discussed above exhibit some homology in their amino acid structure. It is contemplated that due to structural differences between individual src-family kinases and PDGFR kinase, different compounds of the invention may have different inhibitory potencies against individual tyrosine kinases. Thus some of compounds of the invention may also be expected to be most effective in treating diseases mediated by tyrosine kinases that they inhibit most potently.
Particular compounds disclosed herein have been shown to be active inhibitors of p561ck kinase, p60src kinase and PDGFR kinase. See the section entitled "Assessment of Biological Properties" disclosed herein.

In its broadest generic aspect, the invention provides novel compounds of the formula (I) below:
Y~Ar~
~x Het (I) wherein:
Arl is an aromatic or nonaromatic carbocycle, heteroaryl or heterocycle;
wherein said l0 carbocycle, heteroaryl or heterocycle is optionally substituted by one or more Rl, Rz and Rs X is NH, N-C1_3alkyl, N-cyclopropyl, S or O;
15 Y is NRl3x Rl and RZ are the same or different and are selected from H, halogen, CN, NOz, C1_lo branched or unbranched saturated or unsaturated alkyl, Ci_io branched or unbranched alkoxy, Cl_iobranched or unbranched acyl, C1_lobranched or unbranched acyloxy, Cl_lo 2o branched or unbranched alkylthio, aminosulfonyl, di-(C1_3)alkylaminosulfonyl, NR8R9, aryl, aroyl, aryloxy, arylsulfonyl, heteroaryl and heteroaryloxy; wherein the abovementioned Rl and R2 are optionally partially or fully halogenated or optionally substituted with one to three groups independently selected from the group consisting of oxo, OH, NR8R9, C1_6 branched or unbranched alkyl, C3_~cycloalkyl, phenyl, naphthyl, 25 heteroaryl, aminocarbonyl and mono- or di(Cl_3)alkylaminocarbonyl;

R3 is selected from the group consisting of H, halogen, OH, (CH2)"NR~R9, (CH2)"C02Rio, CI_3alkyl optionally substituted with OH, CI_3 alkoxy optionally halogenated and Ci-3 alkylthio;
Het represents a fused heterocylic ring having a formula A, B or C:
R4~.N \ . N \ . R4wN \ .
O' 'N O R~ O R6 N O
H 5 ~ R~ 'H
A B C
R4 is selected from H, C1_6 alkyl branched or unbranched, saturated or unsaturated, and 1o optionally substituted with phenyl, OH or CI_3alkoxy, C3_io-cycloalkyl, or CS_8cycloalkenyl;
or R4 is selected from (CHa)mNR8R9, (CHZ)mNR$CORio, (CHZ)"COZRIO, (CH2)"CONR8R9, phenyl, heteroaryl or heterocycle, each phenyl , heteroaryl or heterocycle being optionally substituted with C1_3alkyl, C1_3alkoxy, (CH2)mNRBR~, OH, S03H or halogen;
1s RS is selected from H, Cl_loalkyl branched or unbranched, C3_io cycloalkyl, CS_7cycloalkenyl, C2_6 allcenyl, C2_6 alkynyl, CI_6acyl, each being optionally substituted with one or more halogen, OH, oxo, CN, C1_6alkyl, Ca_6 alkenyl, CZ_6 alkynyl, C1_3alkoxy, NRgR9, ureido, guanidino, NR$CORIO, SRIO, CONR$R9, C02Rlo, C3_io cycloalkyl, C3_IOCycloalkylidene, CS_7cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle;
2o wherein each of C1_6alkyl, CZ_6 alkenyl, CZ_6 alkynyl, C3_iocycloalkyl, C3_locycloalkylidene, CS_~cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle is optionally substituted with one or more CI_3alkyl, C1_3alkoxy, halogen, CN, N02, amidino, guanidino, (CHz)"NR8R9, or O(CH2)2_øNR$R9; wherein one or more of the amino nitrogens in the ureido, amidino or guanidino groups in this paragraph may be optionally substituted with 2s Ci_3alkyl, phenylCo_3alkyl, C1_3alkoxy or C02Rio;
_g_ or R~ is selected from C02Rlo, NR8R9, CONR$R9, aryl, heteroaryl, heterocycle, aryl-CO-, heteroaryl-CO- or heterocycle-CO-, wherein each aryl, heteroaryl or heterocycle is optionally substituted with one to three:
C1_3alkoxy, halogen, NOa, CN, S(O)PNR8R9, Co_3alkylS(O)p, NR8R9, (CH2)"COaRIO, (CHZ)nCONRBRg, CO(CH2)"NR8R9, O(CH2)2_aNRaR9, ureido, guanidino, cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkyl-Z-, aryl-Z-, heteroaryl-Z-, heterocycle-Z-, or Cl_3alkyl optionally substituted with phenyl or NR$R9, wherein Z is a bridging group selected from C1_io alkylene branched or unbranched, CO, S(O)P, O, S, NH, CONH, NHCO, COO or OOC, and wherein each cycloalkyl, aryl, heteroaryl or heterocycle is optionally substituted with N02, Cl_3alkyl, C1_3alkoxy, halogen, COaRIO, (CHa)"NR8R9, O(CH2)Z~NR8R9, ureido or guanidino, wherein one or more of the amino nitrogens in the ureido or guanidino groups in this paragraph may be optionally substituted with C1_3alkyl, phenylCo_3alkyl or C1_3alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;
or R5 is a C6_iz bridged- or spiro-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 3 carbon atoms in the ring system may be replaced by heteroatoms selected from N, O and S; and wherein said ring system may be 2o optionally substituted with C1_3alkyl, Ci_3alkoxy, halogen, C02Rlo, ureido, guanidino, amidino, (CH~)nNR8R9, or O(CH2)2_4NRsR9i wherein one or more of the amino nitrogens in the ureido, guanidino or amidino groups in this paragraph may be optionally substituted with C1_3alkyl, phenylCo_3alkyl or C1_3alkoxy;
R6 is selected from H, C1_6alkyl branched or unbranched, CZ_6 alkenyl branched or unbranched, C02Rlo, C3-scycloalkyl, C3_scycloalkenyl, aryl, arylCl_3alkyl, heteroaryl and heterocyclyl; wherein said C1_6alkyl, C2_6alkenyl, C3_scycloalkyl, C3_8cycloalkenyl, aryl, arylCl_3alkyl, heteroaryl or heterocyclyl are optionally substituted with OH, CI_3alkoxy, C1_~acyloxy, CO2Rlo, NR11R12, O(CHa)Z_~NRnRl2, aryl, heteroaryl or heterocyclyl;
R7 is H or C1_6alkyl;

R8 and R9 are the same or different and are each independently selected from H, OH, C02RIO, Ci_io acyl branched or unbranched, C1_3alkoxy, C1_6alkyl branched or unbranched, C3_6alkenyl,C3_$cycloalkyl, aryl, arylCl_3alkyl, aroyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, aryl, arylCl_3alkyl, aroyl, heteroaryl or heterocycle are optionally substituted with OH, C1_3alkoxy, C1_3acyloxy, C02RIO, NRIIRIa, O(CH2)a_4NRnRi2, aryl or heteroaryl;
or R8 and R9 together form a 3-7 member alkylene chain completing a ring about the N
to atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, S(O)p, NCORIO, NCOZRIO, NRI I or NC(=NRl l)NRl lRiz; and wherein said ring is optionally substituted by C1_3 alkyl, C1_3alkoxy, OH or -(CHz)nNRIIRI2;
RIO is selected from H, C1_6alkyl, C3_8cycloalkyl, wherein each alkyl or cycloalkyl is 15 optionally substituted with phenyl, OH, C1_3alkoxy, C1_3alkanoyloxy or NR11R1~, or RIO is phenyl optionally substituted with one to three CI_3alkyl, CI_3alkoxy, halogen, (CHZ)",NR$R9, (CH2)"CONR8R9 or O(CH2)2_4NRgRg;
RI I and RI2 are each independently selected from H and CI_6 alkyl optionally substituted 2o with CI_3alkoxy, OH or phenyl;
or RI I and RI~ together form a chain completing a ring, said chain is (CH2)a-s or (CHZ)a0(CH~)Z;
RI3 is H or CI_3alkyl;
P and Q are each independently CH or N;
m is 1-4;
n is 0-3;
and p is 0-2;

wherein one or more of the primary amine or secondary amine nitrogen atoms in any of the R4, R5, R6 and R7 substituent groups may optionally be protected by a protecting group;
and the pharmaceutically acceptable derivatives thereof.
In one embodiment of the invention, there are provided compounds of the formula (I) as described above, and wherein:
Arl is a) a cycloallcyl group selected from cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl and cycloheptanyl;
b) a cycloalkenyl group selected from cyclopentenyl, cyclohexenyl, and cycloheptenyl;
c) an aromatic carbocycle selected from phenyl, naphthyl, indanyl, indenyl, dihydronaphthyl, tetrahydronaphthyl or fluorenyl, d) a heteroaryl selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, 2o benzofuxanyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl, benzothiazolyl, quinazolinyl, and indazolyl,or a fused heteroaryl selected from cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline, cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline, cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole, cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole, cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and cyclohexanothiophene; or e) a heterocycle selected from: pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl and indolinyl;
wherein each of the above Arl are optionally substituted by one or more Rl, RZ
and R3;
Rl and R2 are as defined in claim 1, and R3 is hydrogen, halogen, methyl, methoxy, hydroxymethyl or OH;
to wherein each of the above Arl are optionally substituted by one or more Rl, Ra and R3;
Rl and RZ are as defined in claim 1, and R3 is H, halogen, methyl, methoxy, hydroxymethyl or OH;
15 R4 is H, Ci_3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)z-3NRsR9, (CHZ)"CO2Rlo or (CHZ)"CONR8R9;
RS is selected from H, Cl_loalkyl branched or unbranched, C3_io cycloalkyl, CS_7cycloalkenyl, CZ_6 alkenyl, C2_6 alkynyl, C1_6acyl, each being optionally substituted with 20 one or more halogen, OH, oxo, CN, C1_6alkyl, C2_6 alkenyl, Cz-s alkynyl, C1_3alkoxy, NRgR9, ureido, guanidine, NRBCORio, SRio, CONR8R9, COZRIO, C3-to cycloalkyl, C3-iocycloalkylidene, CS_7cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle;
wherein each of Cl_6alkyl, CZ_6 alkenyl, C2_6 alkynyl, C3_iocycloalkyl, C3-iocycloalkylidene, CS_~cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle is 25 optionally substituted with one or more Cl_3alkyl, Cl_3alkoxy, halogen, CN, N02, amidino, guanidine, (CHa)"NR8R9, or O(CH2)2_4NR8R9; wherein one or more of the amino nitrogens in the ureido, amidino or guanidine groups in this paragraph may be optionally substituted with C1_3alkyl, phenylCo_3alkyl, C1_3alkoxy or CO2Rlo;

or RS is selected from COzRIO, NR$R9, CONR$R9, aryl, heteroaryl, heterocycle, aryl-CO-, heteroaryl-CO- or heterocycle-CO-, wherein each aryl, heteroaryl or heterocycle is optionally substituted with one to three:
C1_3alkoxy, halogen, NOz, CN, S(O)pNR8R9, Co_3alkylS(O)p, NR$R9, (CHz)"C02Rlo, (CHz)"CONR8R9,CO(CHz)"NR8R9,O(CHz)z_4NRgR9, ureido, guanidino, cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkyl-Z-, aryl-Z-, heteroaryl-Z-, heterocycle-Z-, or C1_3alkyl optionally substituted with phenyl or NRgR9, wherein Z is a bridging group selected from Ci-to alkylene branched or unbranched, CO, S(O)p, O, S, NH, CONH, NHCO, COO or l0 OOC, and wherein each cycloalkyl, aryl, heteroaryl or heterocycle is optionally substituted with NOz, Ci-3alkyl, C1_3alkoxy, halogen, COaRIO, (CHz)nNR8R9, O(CHz)z_4NR8R~, ureido or guanidino, wherein one or more of the amino nitrogens in the ureido or guanidino groups in this paragraph may be optionally substituted with CI_3alkyl, phenylCo_3alkyl or Ci-3alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally 15 partially or fully halogenated;
or RS is a C6_iz bridged- or spiro-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 3 carbon atoms in the ring system may be replaced by heteroatoms selected from N, O and S; and wherein said ring system may be 20 optionally substituted with Cl_3alkyl, C1_3alkoxy, halogen, C02Rlo, ureido, guanidino, amidino, (CHz)"NR8R9, or O(CHz)z-4NR8R9i wherein one or more of the amino nitrogens in the ureido, guanidino or amidino groups in this paragraph may be optionally substituted with C1_3alkyl, phenylCo_3allcyl or C1_3alkoxy;
25 R6 is selected from H, CI_6alkyl branched or unbranched, Cz_6 alkenyl branched or unbranched, or C02Rlo; wherein said Cl_6alkyl or Cl_6 alkenyl are optionally substituted with OH, C1_3alkoxy, C1_3acyloxy, C02Rlo, NRllRlz, O(CHz)z-4NW lRiz, aryl, heteroaryl or heterocyclyl;
30 R7 is H or C1_6alkyl;

R8 and R9 are the same or different and are each independently selected from H, OH, Ci_3alkyl branched or unbranched, COzRIO, Cs_gcycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle are optionally substituted with OH, Ci_3alkoxy, Cl_3acyloxy, COZR~o, NRllRia, O(CH2)Z_~NR11Ri2, aryl or heteroaryl;
or R8 and R9 together form a 3-7 member alkylene chain completing a ring about the N
atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, S(O)p, NCORIO, NCOZRIO, NRn or NC(=NRl l)NR11R12; and wherein said ring is to optionally substituted by C1_3 alkyl, Ci_3alkoxy, OH or -(CHZ)"NR11Ri2;
Rlo is H or C1_6alkyl optionally substituted with phenyl, OH, C1_3alkoxy, Cl_3alkanoyloxy or NR11R12;
15 Rl1 and R12 are each independently selected from H and C1_6 alkyl optionally substituted with Cl_3alkoxy, OH or phenyl;
or Rll and Rla together form a chain completing a ring, said chain is (CH2)ø_5 or (CH2)20(CH2)2a R13 is H; and P and Q are each CH.
In another embodiment of the invention, there are provided compounds of the formula (I) as described immediately above, and wherein:
Arl is phenyl or pyridyl, each optionally subsituted by one or more Rl, R2 and R3;
X is NH or N-C1_3alkyl;

Y is NH;
Ri and R2 are the same or different and selected from: halogen, Ci_3 alkyl, wherein the C1_3 alkyl is optionally partially or fully halogenated, NOa, or NR8R9;
R3 is H, halogen, methyl or methoxy;
R4 is H, C1_3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)2-3NRsR9 or COZRIO;
l0 R5 is selected from H, C1_3allcyl branched or unbranched, C3_8 cycloalkyl, CS_~cycloalkenyl or C2_ø alkenyl, each being optionally substituted with one or more OH, CN, NR8R9, CONR8R9, C3_s cycloalkyl, CS_~cycloalkenyl, phenyl, heteroaryl or heterocycle; wherein each phenyl, heteroaryl or heterocycle is optionally substituted with 15 one or more Cl_3alkyl, Cl_3alkoxy, halogen, CN, N02, amidino, guanidino, (CH2)"NRgR9, or O(CH2)z-4NRsR9; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with C1_3alkyl, phenylCo_3alkyl, C1_3alkoxy or C02Rlo;
20 or RS is selected from C02Rlo, NR8R9, CONR8R9, phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl, or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-25 hexahydro-cyclopenta[c]pyrrolyl, benzoyl or indolyl-CO- is optionally substituted with one to three:
halogen, NOZ, S(O)pNR8R9, Co_3a1ky1S(O)p, NR8R9, (CH2)nC02Rlo, ureido, guanidino, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, phenyl-Z-, 30 heteroaryl-Z-, heterocycle-Z-, or Cl_3alkyl optionally substituted with phenyl or NR8R9, wherein Z is a bridging group selected from C1_3 alkylene branched or unbranched, O, S(O)p or NH, and wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with N02, Ci_3alkyl, C1_3alkoxy, C02Rlo, (CH2)"NRBRg, O(CHZ)2_aNRsR9 or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C1_3alkyl, phenylCo_3alkyl or C1_3alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;
or RS is a C6_~ bridged-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 1 carbon atom in the ring system may be to replaced by a nitrogen atom; and wherein said ring system may be optionally substituted with C1_3alkyl, C1_3alkoxy, halogen, (CH2)nNR8R9, or O(CHa)2_aNRgRg;
R6 is selected from H, C1_6alkyl branched or unbranched or COaRIO;
15 R7 is H or C1_6alkyl;
R8 and R9 are the same or different and are each independently selected from H, C1_3alkyl branched or unbranched, C02Rlo, phenyl, or benzoyl; wherein said alkyl, phenyl or benzoyl are optionally substituted with OH or C1_3alkoxy;
or R8 and R9 together form a - (CH2)2-N(C02Rlo)-(CH2)~- group, a -(CHa)2-N(CORIO)-(CH2)a- group, a - (CH2)2-N(Ri i)-(CHa)a- group or a -(CH2)2-N(C(=NRn)NRmRm)-(CHa)2- group; and wherein said ring is optionally substituted by C1_3 alkyl, Ci-3alkoxy, or OH;
Rlo is H or C1_6alkyl optionally substituted with phenyl, OH, C1_3alkoxy, C1_3alkanoyloxy or NRllRiz;
Rn and R12 are each independently selected from H and C1_3 alkyl optionally 3o substituted with C1_3alkoxy or OH;

or Rl l and R12 together form a chain completing a ring, said chain is (CH~)4_5 or (CH2)aO(CH2)a.
In yet another embodiment of the invention there are provided compounds of the formula (I) as described immediately above, and wherein:
Arl is phenyl;
Rl and R2 are the same or different and selected from: halogen, methyl optionally partially or fully halogenated, N02 and NHS;
R3 is H, chloro, fluoro, bromo or methoxy;
RS is selected from C2_4 alkenyl, C3_8 cycloalkyl or CS_~cycloalkenyl, each being optionally substituted with one or more OH, CN, NR8R9, CONR8R9 or phenyl;
wherein phenyl is optionally substituted with one or more C1_3alkyl, Ci_3alkoxy, halogen, amidino, guanidine, (CHa)"NRBR~, or O(CHZ)2_4NRsR9; wherein one or more of the amino nitrogens in the amidino or guanidine groups in this paragraph may be optionally substituted with C1_3alkyl, phenylCo_3alkyl or Cl_3alkoxy;
or RS is selected from phenyl, furyl, thienyl, oxazolyl, thiazolyl , pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, or indolyl-CO- is optionally substituted with one to two:
halogen, N02, SOz,NR8R9, NR8R9, (CHz)nCO2Rto, ureido, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, heteroaryl-Z- or heterocycle-Z-, or Cl_3alkyl optionally substituted Wlth NR8R9, wherein Z is a bridging group selected from Cl_3 alkylene branched or unbranched, wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NOa, Cl_3alkyl, COaRIO, NRgR9 or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C1_3allcyl; and wherein each alkyl and phenyl in this paragraph is optionally partially or fully halogenated;
or RS is a 7-azabicyclo[2.2.1]heptane ring system, optionally having one or two double bonds in the ring system, wherein said ring system may be optionally substituted with C1_3alkyl, Ci_3alkoxy, halogen, (CH2)"NR8R9, or O(CHZ)2_4NR8R9i 1o R6 is selected from H or C1_3alkyl branched or unbranched;
R7 is H or Cl_3alkyl;
R8 and R9 are the same or different and are each independently selected from H
or 15 C1_3alkyl branched or unbranched; wherein said alkyl is optionally substituted with OH or Ci_3alkoxy;
or R8 and R9 together form a - (CH2)z N(C02Rlo)-{CH2)2- , a -(CH~)2-N(CORIO)-(CH2)Z- group, a - (CH2)2-N(Ri i)-(CH2)2- group or a -(CH2)2-N(C(--NRl I)NRi lRi2)-2o (CH2)2- group; and wherein said ring is optionally substituted by CI_3 alkyl, Cl_3alkoxy, or OH;
Rlo is H or C1_3alkyl optionally substituted with phenyl, OH or C1_3allcanoyloxy;
and R11 is selected from H and C1_3 alkyl.
25 In yet another embodiment of the invention, there are provided any of the compounds of formula (I) described above wherein Het represents a fused ring having formula B:

N
~f R/ _N O
H
B
In still another embodiment of the invention, there are provided compounds of the formula (I') below:
Rs R '' P ~Q N
\ ~ H R~
X
Het (I') wherein:
X is NH, N-C1_3alkyl, N-cyclopropyl, S or O;
Rl and R2 are the same or different and are selected from H, halogen, CN, N02, Cl-io branched or unbranched saturated or unsaturated alkyl, Cl_lobranched or unbranched alkoxy, Ci_lobranched or unbranched acyl, Ci_lobranched orunbranched acyloxy, C1_io branched or unbranched alkylthio, aminosulfonyl, di-(C1_3)alkylaminosulfonyl, NR8R9, aryl, aroyl, aryloxy, arylsulfonyl, heteroaryl and heteroaryloxy; wherein the abovementioned Rl and R~ axe optionally partially or fully halogenated or optionally substituted with one to three groups independently selected from the group consisting of oxo, OH, NR8R9, C1_6 branched or unbranched alkyl, C3_7cycloalkyl, phenyl, naphthyl, 2o heteroaryl, aminocarbonyl and mono- or di(C1_3)alkylaminocarbonyl;

R3 is selected from the group consisting of H, halogen, OH, (CH2),;NR8R9, (CHa)"C02Rlo, C1_3alkyl optionally substituted with OH, Ci_3 alkoxy optionally halogenated and CI_3 alkylthio;
Het represents a fused heterocyclic ring having a formula A, B or C:
R4w N ~ . N ~ . Ra.~ N ~ .
O"N O R~N O R6 N O
H 5 H R~ H
A B C
R4 is selected from H, C1_6 alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with phenyl, OH or C1_3alkoxy, C3_io-cycloalkyl, or CS_8cycloalkenyl;
or R4 is selected from (CH2)mNRgR9, (CH2)mNRBCORIO, (CHa)"C02Rlo, (CH2)nCONR8R9, phenyl, heteroaryl or heterocycle, each phenyl , heteroaryl or heterocycle being optionally substituted with C1_3alkyl, C1_3alkoxy, (CH2)mNR8R9, OH, S03H or halogen;
RS is selected from H, C1_ioalkyl branched or unbranched, C3_lo cycloalkyl, CS_~cycloalkenyl, Ca_6 alkenyl, C2_6 alkynyl, C1_6acyl, each being optionally substituted with one or more halogen, OH, oxo, CN, C1_6alkyl, Ca_6 alkenyl, CZ_6 alkynyl, C1_3alkoxy, NR8R9, ureido, guanidino, NRBCOR~o, SRIO, CONR8R9, C02Rlo, C3_lo cycloalkyl, Cs-iocycloalkylidene, CS_~cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle;
wherein each of C1_6alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_locycloalkyl, C3_iocycloalkylidene, CS_~cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle is optionally substituted with one or more Cl_3alkyl, Cl_3alkoxy, halogen, CN, N02, amidino, guanidino, (CH2)nNR8R9, or O(CH2)~~NRsR9; wherein one or more of the amino nitrogens in the ureido, amidino or guanudino groups in this paragraph may be optionally substituted with C1_3alkyl, phenylCo_3alkyl, Ci_3alkoxy or COZRIO;

or RS is selected from C02Rlo, NR8R9, CONR$R9, aryl, heteroaryl, heterocycle, aryl-CO-, heteroaryl-CO- or heterocycle-CO-, wherein each aryl, heteroaryl or heterocycle is optionally substituted with one to three:
Cl_3alkoxy, halogen, N02, CN, S(O)pNR8R9, Co_3alkylS(O)p, NR8R9, (CHa)"C02Rlo, (CHa)"CONRsR9, CO(CH2)nNR8R9, O(CH2)2_4NR8R9, ureido, guanidine, cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkyl-Z-, aryl-Z-, heteroaryl-Z-, heterocycle-Z-, or C1_3alkyl optionally substituted with phenyl or NR8R9, wherein Z is a bridging group selected from Ci-io alkylene branched or unbranched, CO, S(O)p, O, S, NH, CONH, NHCO, COO or to OOC, and wherein each cycloalkyl, aryl, heteroaryl or heterocycle is optionally substituted with N02, C1_3alkyl, C1_3alkoxy, halogen, C02Rlo, (CHZ)"NR8R9, O(CH2)2_4NR8R9, ureido or guanidine, wherein one or more of the amino nitrogens in the ureido or guanidine groups in this paragraph may be optionally substituted with C1_3alkyl, phenylCo_3alkyl or C1_3alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally 15 partially or fully halogenated;
or RS is a Cg_12 bridged- or spire-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 3 carbon atoms in the ring system may be replaced by heteroatoms selected from N, 0 and S; and wherein said ring system may be 20 optionally substituted with C1_~allcyl, C1_3allcoxy, halogen, C02Rlo, ureido, guanidine, amidina, (CH2)nNRgR9, or O(CH2)2_~NRgR9; wherein one or more of the amino nitrogens in the ureido, guanidine or amidino groups in this paragraph may be optionally substituted with C1_3alkyl, phenylCo_3alkyl ar Cl_3alkoxy;
25 R6 is selected from H, C1_6alkyl branched or unbranched, C2_g allcenyl branched or unbranched, COZRIO, C3-scycloalkyl, C3_8cycloalkenyl, aryl, arylCl_3alkyl, heteroaryl and heterocyclyl; wherein said C1_6alkyl, CZ_6alkenyl, C3_8cycloalkyl, C3_$cycloalkenyl, aryl, arylCl_3alkyl, heteroaryl or heterocyclyl are optionally substituted with OH, C1_3alkoxy, C1_ 3acyloxy, COZRIO, NR11Ri2, 0(CH2)2-4NRnRi2, aryl, heteroaryl or heterocyclyl;
R7 is H or C1_6alkyl;

R$ and R9 are the same or different and are each independently selected from H, OH, C02Rlo, Cl_io acyl branched or unbranched, Cl_3alkoxy, Cl_6alkyl branched or unbranched, C3_6alkenyl,C3_$cycloalkyl, aryl, arylCl_3alkyl, aroyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, aryl, arylCl_3alkyl, aroyl, heteroaryl or heterocycle are optionally substituted with OH, C1_3alkoxy, C1_3acyloxy, C02Rlo, NR11R12, O(CHZ)a-4NRuRi2, aryl or heteroaryl;
or R8 and R9 together form a 3-7 member alkylene chain completing a ring about the N
to atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, S(O)p, NCORIO, NC02Rlo, NRl l or NC(=NRI i)NRl iRla; and wherein said ring is optionally substituted by C1_3 alkyl, C1_3alkoxy, OH or -(CH2)nNR~ lRla;
Rlo is selected from H, C1_6alkyl, C3_8cycloalkyl, wherein each alkyl or cycloalkyl is 15 optionally substituted with phenyl, OH, C1_3alkoxy, C1_3alkanoyloxy or NRI1RI2, or Rlo is phenyl optionally substituted with one to three C1_3alkyl, C1_3alkoxy, halogen, (CH2)mNRaR9, (CH2)nCONR$R9 or O(CH2)2_4NRsR9;
R~1 and R12 are each independently selected from H and C1_6 alkyl optionally substituted 2o with Cl_3alkoxy, OH or phenyl;
or Rl1 and Rlz together form a chain completing a ring, said chain is (CH~)4_5 or (CH2)20(CH2)2i Rl~ is H or C1_3alkyl;
P and Q are each independently CH or N;
m is 1-4;
n is 0-3;
and p is 0-2;

wherein one or more of the primary amine or secondary amine nitrogen atoms in any of the R4, R5, R6 and R~ substituent groups may optionally be protected by a protecting group;
and the pharmaceutically acceptable derivatives thereof.
In another embodiment of the invention there are provided compounds of the formula(I') as described above, and wherein:
X is NH or N-C1_3allcyl;
to R1 and R2 are the same or different and selected from: halogen, Ci_3 alkyl, wherein the C1_3 alkyl is optionally partially or fully halogenated, NOa or NR$R9;
R3 is H, halogen, methyl or methoxy;
R4 is H, Ci_3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)z_3NRaR~ or C02Rlo;
RS is selected from H, C1_3alkyl branched or unbranched, C3_$ cycloalkyl, 2o CS_7cycloalkenyl or C2~ alkenyl, each being optionally substituted with one or more OH, CN, NR8R9, CONRgR9, C3_8 cycloalkyl, CS_~cycloalkenyl, phenyl, heteroaryl or heterocycle; wherein each phenyl, heteroaryl or heterocycle is optionally substituted with one or more C1_3alkyl, Cl_3alkoxy, halogen, CN, N02, amidino, guanidine, (CHa)"NR8R9, or O(CH2)2_~NRgR9; wherein one or more of the amino nitrogens in the amidino or ~5 guanidine groups in this paragraph may be optionally substituted with C1_3allcyl, phenylCo_ 3alkyl, C1_3alkoxy or COZRIO;
or RS is selected from C02Rlo, NR$R9, CONR8R9, phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-3o pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl, or indolyl CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl or indolyl-CO- is optionally substituted with one to three:
halogen, NOz, S(O)pNRBRg, Co_3a1ky1S(O)p, NR8R9, (CHz)"COaRIO, ureido, guanidino, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, phenyl-Z-, heteroaryl-Z-, heterocycle-Z-, or C1_3alkyl optionally substituted with phenyl or NR$Rs, wherein Z is a bridging group selected from C1_3 alkylene branched or unbranched, O, S(O)p or NH, and wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NOz, C1_3alkyl, C1_3alkoxy, C02Rlo, (CHz)"NR$R9, O(CHz)z_4NR8R9 or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C1_3alkyl, phenylCo_3alkyl or Cl_3allcoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;
or RS is a C6_7 bridged-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 1 carbon atom in the ring system may be replaced by a nitrogen atom; and wherein said ring system may be optionally substituted with C1_3alkyl, C1_3alkoxy, halogen, (CHz)"NR8R9, or O(CHz)2_4NRgRg;
R6 is selected from H, C1_6alkyl branched or unbranched or C02Rlo;
R~ is H or C1_6alkyl;
R$ and R9 are the same or different and are each independently selected from H, C1_3alkyl branched or unbranched, COZRIO, phenyl, or benzoyl; wherein said alkyl, phenyl or benzoyl are optionally substituted with OH or Cl_3alkoxy;
or R8 and R9 together form a - (CHz)z-N(COZRIO)-(CHz)z- group, a -(CHz)z-N(CORio)-(CHz)z- group, a - (CHz)z-N(Rll)-(CHz)z- group or a -(CHz)z-N(C(=NRl l)NR11R12)-(CHz)2- group; and wherein said ring is optionally substituted by C1_3 alkyl, Ci_3alkoxy, or OH;
Rlo is H or C1_6allcyl optionally substituted with phenyl, OH, C1_3alkoxy, Cl_3alkanoyloxy or NRllRiz;
Rl1 and R12 are each independently selected from H and C1_3 alkyl optionally substituted with Cl_3alkoxy or OH;
l0 or Rl l and R12 together form a chain completing a ring, said chain is (CH~)4_5 or (CHZ)a0(CH2)a; and P and Q are each CH, In still a further embodiment of the invention there are provided compounds of the formula 15 (I') as described immediately above, and wherein:
Rl and R2 are the same or different and selected from: halogen, methyl optionally partially or fully halogenated, N02 and NHa;
R3 is H, chloro, fluoro, bromo or methoxy;
RS is selected from CZ_4 alkenyl, C3_$ cycloalkyl or CS_~cycloalkenyl, each being optionally substituted with one or more OH, CN, NR8R9, CONR8R9 or phenyl;
wherein phenyl is optionally substituted with one or more Cl_3alkyl, Cl_3alkoxy, halogen, amidino, guanidino, (CH2)nNR8R9, or O(CH~)2_4NRgR9; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with Ci_3alkyl, phenylCo_3alkyl or Ci_3alkoxy;
or RS is selected from phenyl, furyl, thienyl, oxazolyl, thiazolyl , pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-3o cyclopenta[c]pyrrolyl or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO- is optionally substituted with one to two:
halogen, NO2, SO~NR&R9, NR$R9, (CH2)nC02Rlo, ureido, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, heteroaryl-Z- or heterocycle-Z-, or Cl_3aLkyl optionally substituted with NR8R9, wherein Z is a bridging group selected from Cl_3 alkylene branched or unbranched or S(O)p, wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO2, C1_3alkyl, C02Rlo, NR8R9 or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may to be optionally substituted with C1_3alkyl; and wherein each alkyl and phenyl in this paragraph is optionally partially or fully halogenated;
or RS is a 7-azabicyclo[2.2.1]heptane ring system, optionally having one or two double bonds in the ring system, wherein said ring system may be optionally substituted 15 with C1_3alkyl, C1_3alkoxy, halogen, (CH2)"NR8R9, or O(CH2)2_4NR8R9i R6 is selected from H or C1_3alkyl branched or unbranched.
R7 is H or C1_3alkyl;
R8 and R9 are the same or different and are each independently selected from H
or C1_3alkyl branched or unbranched; wherein said alkyl is optionally substituted with OH or C1_3alkoxy;
or R8 and R9 together form a - (CH2)a-N(COZRIO)-(CH2)2- , a -(CH2)z-N(GORIO)-(CHz)2- group, a - (CH2)2-N(Rl l)-(CH2)2- group or a -(CH2)2-N(C(--NRl l)NR11Ri2)-(CH2)2- group; and wherein said ring is optionally substituted by C1_3 alkyl, C1_3alkoxy, or OH;
3o Rlo is H or C1_3allcyl optionally substituted with phenyl, OH or C1_3alkanoyloxy;
and Rl1 is selected from H and CI_3 alkyl.
In yet another embodiment of the invention, there are provided any of the compounds of formula (I') described above wherein Het represents a fused ring having formula B:
\ .
N
R~N O
H
_5 In yet another aspect of the invention, there are provided compounds of the following farmula Ib:
/ N Are \ ~ \~ H
N ~N
R

Ib 1o wherein R is H, CI_3alleyl or cyclopropyl, and Arl and RS are as defined in formula (I) above.
The present invention is also directed to the intermediate compounds of the following formulae (VI), (XII), (XVIII) and (XIX) useful in the synthetic schemes and examples set forth below.
Formula (VIA
In their broadest generic aspect, intermediate compounds of the formula (VI) are represented by the following formula:

R4~
N ~NHR
O' _N O
H
VI
wherein:
R is H, C1_3alkyl or cyclopropyl;
R4 is selected from H, C1_6 alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with phenyl, OH or Cl_3alkoxy; or R4 is selected from (CH2)mNRgR9, (CHa)mNRBCORIO, (CHa)nCOzRio or (CHa)"CONRgR9;
to Rg and R9 are the same or different and are each independently selected from H, OH, C02Rlo, Cl_io aryl branched or unbranched, Cl_3alkoxy, Cl_6alkyl branched or unbranched, C3_6alkenyl,C3_8cycloalkyl, aryl, arylCl_3alkyl, aroyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, aryl, arylCl_3alkyl, aroyl, heteroaryl or heterocycle are optionally 15 substituted with OH, C1_3alkoxy, C1_3acyloxy, C02Rlo, NR11RI2, O(CH2)2_4NR11R12, aryl or heteroaryl;
or R8 and R9 together form a 3-7 member alkylene chain completing a ring about the N
atom to which they are attached; wherein said alkylene chain is optionally interrupted by 2o O, S(O)P, NCORIO, NC02Rlo, NRl l or NC(--NRII)NRnRi2; and wherein said ring is optionally substituted by C1_3 alkyl, Ci_3alkoxy, OH or -(CHZ)nNRnRl2;
Rlo is selected from H, C1_6alkyl, C3_8cycloalkyl, wherein each alkyl or cycloalkyl is optionally substituted with phenyl, OH, Cl_3alkoxy, Cl_3alkanoyloxy or NRl lRlz, or Rlo is phenyl optionally substituted with one to three C1_3alkyl, Ci_3alkoxy, halogen, (CHa)",NR8R9, (CHZ)"CONR$R9 or O(CHZ)2_4~8R9;
Rl l and R12 are each independently selected from H and C1_6 alkyl optionally substituted with C1_3alkoxy, OH or phenyl;
or Rl1 and R12 together form a chain completing a ring, said chain is (CH2)4-s or (CH2)20(CHZ)~;
m is 1-4;
n is 1-3;
and p is 0-2;
wherein one or more of the primary amine or secondary amine nitrogen atoms in the R4 substituent group may optionally be protected by a protecting group.
One embodiment of the compounds of formula(VI) are those wherein:
R is H or C1_3alkyl; and R4 is H, C1-3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)a-sNRaR9a (CH~)"C02Rm or (CH2)"CONR8R9, Formula ~XIII
In their broadest generic aspect, intermediate compounds of formula (XII) are represented by the following formula:

HR
R, XII

wherein:
R is H, C1_3alkyl or cyclopropyl; and RS is selected from H, CI_ioalkyl branched or unbranched, C3_io cycloalkyl, CS_7cycloalkenyl, C2_6 alkenyl, C2_6 allcynyl, C1_6acyl, each being optionally substituted with one or more halogen, OH, oxo, CN, C1_6alkyl, Ca_6 alkenyl, C2_6 alkynyl, Cl_3alkoxy, NRBRs, ureido, guanidine, NR$CORIO, SRIO, CONRgR9, C02Rlo, C3-io cycloalkyl, C3-iocycloalkylidene, CS_~cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle;
wherein each of C1_6alkyl, CZ_6 alkenyl, Ca_6 alkynyl, C3_iocycloalkyl, C3-iocycloalkylidene, CS_7cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle is optionally substituted with one or more C1_3alkyl, C1_3alkoxy, halogen, CN, N02, amidino, guanidine, (CH~)"NR8R9, or O(CH2)2_4NR8R9i wherein one or more of the amino nitrogens in the ureido, amidino or guanidine groups in this paragraph may be optionally substituted with C1_3alkyl, phenylCo_3alkyl, CI_3alkoxy or COZRIO;
or RS is selected from C02Rlo, NR8R9, CONR8R9, aryl, heteroaryl, heterocycle, aryl-CO-, heteroaryl-CO- or heterocycle-CO-, wherein each aryl, heteroaryl or heterocycle is optionally substituted with one to three:
C1_3alkoxy, halogen, NO2, CN, S(O)pNR8R9, Co_3a1ky1S(O)p, NR8R9, (CH2)"C02R1o, (CH2)"CONR8R9, CO(CHa)"NR8R9, O(CH2)2_4NRSR9, ureido, guanidine, cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkyl-Z-, aryl-Z-, heteroaryl-Z-, heterocycle-Z-, or C1_3alkyl optionally substituted with phenyl or NR$R9, wherein Z is a bridging group selected from Ci_lo alkylene branched or unbranched, CO, S(O)p, O, S, NH, CONH, NHCO, COO or OOC, and wherein each cycloalkyl, aryl, heteroaryl or heterocycle is optionally substituted with N02, Ci_3alkyl, C1_3alkoxy, halogen, C02Rlo, (CH2)"NR8R9, O(CH2)2_~NRBRg, ureido or guanidine, wherein one or more of the amino nitrogens in the ureido or guanidine groups in this paragraph may be optionally substituted with C1_3alkyl, phenylCo_3alkyl or 3o C~_3alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;

or RS is a C6_iz bridged- or spiro-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 3 carbon atoms in the ring system may be replaced by heteroatoms selected from N, O and S; and wherein said ring system may be optionally substituted with C1_3alkyl, Cl_3alkoxy, halogen, C02Rlo, ureido, guanidino, amidino, (CH2)nNR8R9, or O(CHZ)2_4NRSR9i wherein one or more of the amino nitrogens in the ureido, guanidino or amidino groups in this paragraph may be optionally substituted with Cl_3alkyl, phenylCo_3alkyl or Cl_3alkoxy;
to Rs is selected from H, C1_6alkyl branched or unbranched, Ca_6 alkenyl branched or unbranched, C02Rlo, C3_8cycloallcyl, C3_8cycloalkenyl, aryl, arylCl_3alkyl, heteroaryl and heterocyclyl; wherein said C1_6alkyl, C~_6alkenyl, C3_8cycloalkyl, C3_8cycloalkenyl, aryl, arylCl_salkyl, heteroaryl or heterocyclyl are optionally substituted with OH, C1_3alkoxy, C1_ 3acyloxy, C02Rlo, NR11R12, O(CH2)a_4NRi 1812, aryl, heteroaryl or heterocyclyl;
is R7 is H or C1_6alkyl;
R$ and R9 are the same or different and are each independently selected from H, OH, C02Rio, C1_io acyl branched or unbranched, Ci_3alkoxy, C1_6alkyl branched or unbranched, 2o C3_6alkenyl,C3_8cycloalkyl, aryl, arylCl_3alkyl, amyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, aryl, arylCl_3alkyl, aroyl, heteroaryl or heterocycle are optionally substituted with OH, C1_3alkoxy, C1_3acyloxy, COZRIO, NR11R12, O(CH2)2_4NR11R12, aryl or heteroaryl;
25 or Rg and R9 together form a 3-7 member alkylene chain completing a ring about the N
atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, S(O)p, NCORIO, NC02Rlo, NRl or NC(=NRl)NRnRi2; and wherein said ring is optionally substituted by C1_3 allcyl, C1_3alkoxy, OH or -(CH2)"NRnRIZ~
3o Rio is selected from H, C1_6alkyl, C3_8cycloalkyl, wherein each alkyl or cycloalkyl is optionally substituted with phenyl, OH, C1_3alkoxy, C1_3alkanoyloxy or NR11Ri2, or Rlo is phenyl optionally substituted with one to three C1_3alkyl, C1_3alkoxy, halogen, (CH2)mNRsR9, (CHa)nCONRgR9 or O(CH2)2_4NR8R9;
Rll and R12 are each independently selected from H and C1_6 alkyl optionally substituted with C1_3alkoxy, OH or phenyl;
or Rl1 and Rla together form a chain completing a ring, said chain is (CHZ)a-s or (CH2)20(CH2)2;
m is 1-4;
n is 0-3;
and p is 0-2;
wherein one or more of the primary amine or secondary amine nitrogen atoms in any of the R4, R5, R.6 and R7 substituent groups may optionally be protected by a protecting group.
One embodiment of the compounds of formula (XTI) are those wherein:
R is H or Cl_3alkyl; and 2o RS is selected from H, Ci_3alkyl branched or unbranched, C3_8 cycloalkyl, CS_~cycloalkenyl or CZ_4 alkenyl, each being optionally substituted with one or more OH, CN, NR8R9, CONR8R9, C3_8 cycloalkyl, Cs_~cycloalkenyl, phenyl, heteroaryl or heterocycle; wherein each phenyl, heteroaryl or heterocycle is optionally substituted with one or more C1_3alkyl, C1_3alkoxy, halogen, CN, NOa, amidino, guanidino, (CHa)nNR8R9, or O(CH~)a_4NR8R9; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with Cl_3alkyl, phenylCo_3alkyl, C1_3alkoxy or C02Rlo;
or Rj is selected from C02Rlo, NR8R9, CONRgR9, phenyl, furyl, thienyl, oxazolyl, 3o thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl, or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl or indolyl-CO- is optionally substituted with one to three:
halogen, NOZ, S(O)pNR8R9, Co_3alkylS(O)p, NR8R9, (CHZ)nC02Rlo, ureido, guanidine, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, phenyl-Z-, heteroaryl-Z-, heterocycle-Z-, or C1_3alkyl optionally substituted with phenyl or NR8R9, wherein Z is a bridging group selected from C1_3 alkylene branched or unbranched, O, S(O)p or NH, and wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NOz, Cl_3alkyl, C1_3alkoxy, C02R1o, (CH2)nNRgR9, O(CH2)2_4NR8R9 or guanidine, wherein one or more of the amino nitrogens in the guanidine group in this paragraph may be optionally substituted with C1_3alkyl, phenylCo_3alkyl or C1_3alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;
or R5 is a C6_7 bridged-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 1 carbon atom in the ring system may be replaced by a nitrogen atom; and wherein said ring system may be optionally substituted 2o with C1_3alkyl, C1_3alkoxy, halogen, (CH2)"NR8R9, or O(CH2)2_4NRgR9;
Yet another embodiment of the compounds of formula (XII) are those described immediately above, wherein:
RS is selected from C2_4 alkenyl, C3_g cycloalkyl or CS_7cycloalkenyl, each being optionally substituted with one or more OH, CN, NR8R9, CONR8R9 or phenyl;
wherein phenyl is optionally substituted with one or more C1_3alkyl, C1_3alkoxy, halogen, amidino, guanidine, (CH~)nNR8R9, or O(CH2)a-4NR8R9i wherein one or more of the amino nitrogens in the amidino or guanidine groups in this paragraph may be optionally substituted with 3o C1_3alkyl, phenylCQ_3alkyl or Cl_3alkoxy;

or RS is selected from phenyl, furyl, thienyl, oxazolyl, thiazolyl , pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO- is optionally substituted with one to two:
halogen, N02, S02NR8R9, NR8R9, (CH~)"C02Rlo, ureido, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, heteroaryl-Z- or heterocycle-Z-, or C1_3alkyl optionally substituted with NR8R9, wherein Z is a bridging group selected from C1_3 1o alkylene branched or unbranched or S(O)p, wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NOz, Ci_3alkyl, C02Rm, NR8R9 or guanidine, wherein one or more of the amino nitrogens in the guanidine group in this paragraph may be optionally substituted with C1_3alkyl; and wherein each alkyl and phenyl in this paragraph is optionally partially or fully halogenated;
or RS is a 7-azabicyclo[2.2.1]heptane ring system, optionally having one or two double bonds in the ring system, wherein said ring system may be optionally substituted with C1_3alkyl, C1_3alkoxy, halogen, (CHa)nNR8R9, or O(CHz)z_4NR8R9;
Formula (XVIII~
In their broadest generic aspect, intermediate compounds of the formula (XVIII) are represented by the following formula:
/ ~ ~~N~Ar~
R4~N \ N H
H
CN R
XVI I I
wherein:

Ari is an aromatic or nonaromatic carbocycle, heteroaryl or heterocycle;
wherein said carbocycle, heteroaryl or heterocycle is optionally substituted by one or more Rl, Rz and R is H, C1_3alkyl or cyclopropyl;
Rl and R2 are the same or different and are selected from H, halogen, CN, N02, C1_io branched or unbranched saturated or unsaturated alkyl, C1_IO branched or unbranched alkoxy, Cl_iobranched or unbranched acyl, Cl_lobranched or unbranched acyloxy, Cl_io to branched or unbranched alkylthio, aminosulfonyl, di-(C1_3)alkylaminosulfonyl, NR8R9, aryl, amyl, aryloxy, arylsulfonyl, heteroaryl and heteroaryloxy; wherein the abovementioned Rl and Ra are optionally partially or fully halogenated or optionally substituted with one to three groups independently selected from the group consisting of oxo, OH, NR8R9, Cl_6 branched or unbranched alkyl, C3_7cycloalkyl, phenyl, naphthyl, i5 heteroaryl, aminocarbonyl and mono- or di(C1_3)alkylaminocarbonyl;
R3 is selected from the group consisting of H, halogen, OH, (CH2)nNR8R9, (CH2)nC02Rto~
C1_3alkyl optionally substituted with OH, Ci_3 alkoxy optionally halogenated and CI_3 alkylthio;
R4 is selected from H, C1_6 alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with phenyl, OH or C1_3alkoxy, C3_lo-cycloalkyl, or CS_8cycloalkenyl;
or R4 is selected from (CH2)mNR8R9, (CHZ)mNRBCORIO, (CHa)"COzRio, (CHa)nCONR$R9, phenyl, heteroaryl or heterocycle, each phenyl , heteroaryl or heterocycle being optionally substituted with C1_3alkyl, C1_3alkoxy, (CHZ)mNR8R9, OH, S03H or halogen;
Rg and R9 are the same or different and are each independently selected from H, OH, COZRIO, Ci-to acyl branched or unbranched, C1_3alkoxy, Cl_6alkyl branched or unbranched, C3_6alkenyl,C3_$cycloalkyl, aryl, arylCl_3alkyl, amyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, aryl, arylCl_3alkyl, aroyl, heteroaryl or heterocycle are optionally substituted with OH, C~_3alkoxy, C1_3acyloxy, C02Rlo, NR11R12, O(CH2)Z_~NRuRl2, aryl or heteroaryl;
or R$ and R9 together form a 3-7 member alkylene chain completing a ring about the N
atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, S(O)p, NCORIO, NC02Rlo, NRn or NC(=NRl l)NRIRiz; and wherein said ring is optionally substituted by CI_3 alkyl, C1_3alkoxy, OH or -(CH2)nNRI tRi2~
Rlo is selected from H, C1_6alkyl, C3_8cycloalkyl, wherein each alkyl or cycloalkyl is optionally substituted with phenyl, OH, C1_3alkoxy, C1_3alkanoyloxy or NRllRiz, or Rlo is to phenyl optionally substituted with one to three C1_3alkyl, C1_3alkoxy, halogen, (CHZ)mNR8R9, (CH2)"CONRgR9 or O(CH2)2_~NR8R9;
Rll and Rl2 are each independently selected from H and C1_6 alkyl optionally substituted with CI_3alkoxy, OH or phenyl;
15 or Rl1 and Rla together form a chain completing a ring, said chain is (CH2)~_5 or (CHZ)ZO(CH2)a;
m is 1-4;
n is 0-3;
20 and p is 0-2;
wherein one or more of the primary amine or secondary amine nitrogen atoms in any of the R4, R5, R6 and R7 substituent groups may optionally be protected by a protecting group.
25 One embodiment of the compounds of formula (XVIII) are those wherein:
Arl is a) a cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl and cycloheptanyl;
30 b) a cycloalkenyl group selected from cyclopentenyl, cyclohexenyl, and cycloheptenyl;

c) an aromatic carbocycle selected from phenyl, naphthyl, indanyl, indenyl, dihydronaphthyl, tetrahydronaphthyl or fluorenyl, d) a heteroaryl selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl, benzothiazolyl, quinazolinyl, and indazolyl,or a fused heteroaryl selected from cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, 1o cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline, cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline, cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole, cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole, cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and cyclohexanothiophene; or e) a heterocycle selected from: pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl and indolinyl;
wherein each of the above Arl are optionally substituted by one or more RI, R2 and R3;
Rl and RZ are as defined in claim 1, and R3 is hydrogen, halogen, methyl, methoxy, hydroxymethyl or OH; and R4 is H, Ci_3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)z-sNRsR9, (CH2)"C02Rlo or (CH2)nCONRsR9;
Rs and R9 are the same or different and are each independently selected from H, OH, Cl_3alkyl branched or unbranched, C02Rlo, C3_scycloalkyl, phenyl, benzyl, benzoyl, 3o heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle are optionally substituted with OH, Cl_3alkoxy, Ci_3acyloxy, COZRIO, NR11R12, O(CHa)2_4NR11Rlz, aryl or heteroaryl;
or R$ and R9 together form a 4-6 member alkylene chain completing a ring about the N
atom to which they are attached; wherein said alkylene chain is optionally interrupted by NC02Rlo or NRi i; and wherein said ring is optionally substituted by Cl_3 alkyl, CI_3alkoxy, OH or -(CH2)"NRl iRt2;
Rlo is H or C1_6alkyl optionally substituted with phenyl, OH, C1_3alkoxy or NRlIRm;
to R11 and R12 are each independently selected from H and C1_6 alkyl optionally substituted with C1_3alkoxy, OH or phenyl;
or Rl1 and R12 together form a chain completing a ring, said chain is (CH2)a-s or 1s (CH2)ZO(CH2)2; and n is 0-3.
Yet another embodiment of the compounds of formula (XVIII) are those described 20 immediately above, wherein:
Arl is phenyl or pyridyl, each optionally substituted by one or more Rl, R2 and R3;
R is H or Cl_3alkyl;
R1 and R2 are the same or different and selected from: halogen, C1_3 alkyl, wherein the C1_3 alkyl is optionally partially or fully halogenated, N02 or NR8R9;
R3 is H, halogen, methyl or methoxy;

R4 is H, C1_3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CHZ)a-3NRaR9 or COaRIO;
R$ and R9 are the same or different and are each independently selected from H, Ci_3alkyl branched or unbranched, COZRio, phenyl, or benzoyl; wherein said alkyl, phenyl or benzoyl are optionally substituted with OH or Cl_3alkoxy;
or R8 and R9 together form a - (CHa)2-N(C02Rlo)-(CH2)2- group or a - (CH2)z-N(Rl1)-(CH2)~- group; and wherein said ring is optionally substituted by C1_3 alkyl, C1_ l0 3alkoxy, or OH;
Rlo is H or Cl_3alkyl optionally substituted with phenyl, OH, C1_3alkoxy or NRl iRia;
15 Rl l and R12 are each independently selected from H and CI_3 alkyl optionally substituted with C1_3alkoxy or OH;
or Rll and R12 together form a chain completing a ring, said chain is (CH2)~5 or (CH2)2O(CH2)a.
Formula (XIX~
In their broadest generic aspect, intermediate compounds of formula (XIX) are represented by the following formula:
/ N Are I \~--N
R4~N ~ N H
H
R

XIX

wherein:
Arl is an aromatic or nonaromatic carbocycle, heteroaryl or heterocycle;
wherein said carbocycle, heteroaryl or heterocycle is optionally substituted by one or more Rl, R2 and R3 a R is H, C1_3allcyl or cyclopropyl Rl and Ra are the same or different and are selected from H, halogen, CN, NOa, Ci-io 1o branched or unbranched saturated or unsaturated alkyl, C1_lo branched or unbranched alkoxy, C1_io branched or unbranched acyl, C1-io branched or unbranched acyloxy, Ci_io branched or unbranched alkylthio, aminosulfonyl, di-(C1_3)alkylaminosulfonyl, NR8R9, aryl, aroyl, aryloxy, arylsulfonyl, heteroaryl and heteroaryloxy; wherein the abovementioned Rl and Ra are optionally partially or fully halogenated or optionally 15 substituted with one to three groups independently selected from the group consisting of oxo, OH, NR$R9, Ci-6 branched or unbranched alkyl, C3_~cycloalkyl, phenyl, naphthyl, heteroaryl, aminocarbonyl and mono- or di(Ci_3)allcylaminocarbonyl;
R3 is selected from the group consisting of H, halogen, OH, (CH~)"NR8R9, (CH2)"C02Rio, 20 C1_3alkyl optionally substituted with OH, Ci_3 alkoxy optionally halogenated and Ci_3 alkylthio;
R4 is selected from H, Cl_6 alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with phenyl, OH or C1_3alkoxy, C3_io-cycloalkyl, or CS_8cycloalkenyl;
25 or R4 is selected from (CHZ)mNR$R9, (CH2)mNRBCORIO, (CHz)"CO2Rlo, (CH2)"CONR8R9, phenyl, heteroaryl or heterocycle, each phenyl , heteroaryl or heterocycle being optionally substituted with C1_3alkyl, Ci-3alkoxy, (CHa)mNR8R9, OH, S03H or halogen;
R8 and R9 are the same or different and are each independently selected from H, OH, 3o COZRIO, Ci-to acyl branched or unbranched, C1_3alkoxy, C1_6alkyl branched or unbranched, C3_6alkenyl,C3.scycloallcyl, aryl, arylCl_3alkyl, aroyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, aryl, arylCl_3alkyl, aroyl, heteroaryl or heterocycle are optionally substituted with OH, C1_3alkoxy, Ci_3acyloxy, C02Rlo, NR11R12, O(CH2)a_4NR11Riz, aryl or heteroaryl;
or R$ and R9 together form a 3-7 member alkylene chain completing a ring about the N
atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, S(O)p, NCORIO, NC02Rlo, NRl for NC(--NRI I)NRnRi2; and wherein said ring is optionally substituted by C1_3 alkyl, C1_3alkoxy, OH or -(CH2)nNRl1R12;
to Rlo is selected from H, C1_6alkyl, C3_gcycloalkyl, wherein each alkyl or cycloalkyl is optionally substituted with phenyl, OH, C1_3alkoxy, Cl_3alkanoyloxy or NRllRia, or Rlo is phenyl optionally substituted with one to three CI-3alkyl, C1_3alkoxy, halogen, (CH2)mNRgR9, (CH2)"CONR8R9 or O(CH2)2_4NRaR9;
15 Rl l and Rl~ are each independently selected from H and C1_6 alkyl optionally substituted with C1_3alkoxy, OH or phenyl;
or Rl1 and R12 together form a chain completing a ring, said chain is (CHZ)a-s or (CH2)z0(CH2)z~
2o m is 1-4;
n is 0-3;
and p is 0-2;
wherein one or more of the primary amine or secondary amine nitrogen atoms in any of the 25 R4, R,~, Rb and R7 substituent groups may optionally be protected by a protecting group.
One embodiment of the compounds of formula (XIX) above is wherein:
Arl is 30 a) a cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl and cycloheptanyl;

b) a cycloalkenyl group selected from cyclopentenyl, cyclohexenyl, and cycloheptenyl;
c) an aromatic carbocycle selected from phenyl, naphthyl, indanyl, indenyl, dihydronaphthyl, tetrahydronaphthyl or fluorenyl, d) a heteroaryl selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofizranyl, benzothiazolyl, quinazolinyl, and indazolyl,or a fused heteroaryl selected from to cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline, cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline, cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole, cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole, cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and cyclohexanothiophene; or e) a heterocycle selected from: pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl and indolinyl;
wherein each of the above Arl are optionally substituted by one or more Rl, R2 and R3;
Rl and RZ are as defined in claim 1, and R3 is hydrogen, halogen, methyl, methoxy, hydroxymethyl or OH; and Rd is H, Ci_3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)2_3NR8R9, (CH2)nC02Rm or (CHz)nCONR8R9;
3o R8 and R9 are the same or different and are each independently selected from H, OH, Cl_3alkyl branched or unbranched, C02Rlo, C3_8cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle are optionally substituted with OH, Ci_3alkoxy, Ci_3acyloxy, COZRIO, NR11R12, O(CH2)2_4NRnR12, aryl or heteroaryl;
or R8 and R9 together form a 4-6 member alkylene chain completing a ring about the N
atom to which they are attached; wherein said alkylene chain is optionally interrupted by NC02Rlo or NRII; and wherein said ring is optionally substituted by C1_3 alkyl, Cl_3alkoxy, OH or -(CHa)"NRnRi2;
to Rlo is H or C1_6alkyl optionally substituted with phenyl, OH, C1_3alkoxy or NR11R12;
Rl and R12 are each independently selected from H and C1_6 alkyl optionally substituted with C1_3alkoxy, OH or phenyl;
15 or Rlz and Rla together form a chain completing a ring, said chain is (CHZ)4-s or (CH2)20(CH2)2; and n is 0-3.
2o Yet another embodiment of the compounds of formula (XIX) are those described immediately above, wherein:
Arl is phenyl or pyridyl, each optionally substituted by one or more Rl, Ra and R3;
25 R is H or C1_3alkyl;
Rl and R2 are the same or different and selected from: halogen, C1_3 alkyl, wherein the Ci_3 alkyl is optionally partially or fully halogenated, NOZ or NR8R9;
R3 is H, halogen, methyl or methoxy;

R4 is H, Cl_3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)z-3NRaRs or C02Rlo;
R$ and R9 are the same or different and are each independently selected from H, Cl_3alkyl branched or unbranched, C02Rlo, phenyl, or benzoyl; wherein said alkyl, phenyl or benzoyl are optionally substituted with OH or C1_3alkoxy;
or R8 and R9 together form a - (CHZ)a-N(COaRIO)-(CHZ)2- group or a - (CH2)2-N(Rll)-(CH2)a- group; and wherein said ring is optionally substituted by C1_3 alkyl, C1_ 3alkoxy, or OH;
to Rlo is H or C1_3alkyl optionally substituted with phenyl, OH, Cl_3alkoxy or NRl iRia;
Rl l and R12 are each independently selected from H and C1_3 alkyl optionally 15 substituted with C1_3alkoxy or OH;
or Rl l and Rl2 together form a chain completing a ring, said chain is (CHa)4_5 or (CH2)20(CH~)~, 20 In a further embodiment of the invention, there are provided the following compounds of the formula (I):
2-(2,6-Dichlorophenylamino)-1-methyl-1,8-dihydro-9H imidazo[4,5 f]quinazoline-9-one;
25 2-(2,6-Dichlorophenylamino)-7-furan-2-yl-1-methyl-1,8-dihydro-9H
imidazo[4,5-f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-1-methyl-7-phenyl-1,8-dihydro-9H imidazo[4,5-f]quinazoline-9-one;

2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-nitrophenyl)-1,8-dihydro-9H
imidazo[4,5-f]quinazoline-9-one;

7-(3-Aminophenyl)-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H
imidazo[4,5-f]quinazoline-9-one;
1- f 3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H imidazo[4,5-f]quinazolin-7-yl]-phenyl}-3-ethylurea;
2-(2,6-Dichlorophenylamino)-1-methyl-7-vinyl-1,8-dihydro-9H imidazo[4,5-f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-1-methyl-7-thiophen-2-yl-1,8-dihydro-9H
imidazo[4,5-f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-1-methyl-7-[2-(3-nitrophenyl)-thiazol-4-yl]-1,8-dihydro-9H
imidazo[4,5 f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-7-imidazol-2-yl-1-methyl-1,8-dihydro-9H
imidazo[4,5-2o f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-phenyloxazol-5-yl)-1,8-dihydro-9H
imidazo[4,5 f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H imidazo[4,5 f]quinazoline-7-carboxamide;
2-(2, 6-Dichlorophenylamino)-1-methyl-7-(2-methylpropen-1-yl)-1, 8-dihydro-9H
imidazo[4,5 f]quinazoline-9-one;

2-(2,6-Dichlorophenylamino)-1-methyl-7-pyridin-2-yl-1,8-dihydro-9H imidazo[4,5-f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-1-methyl-7-pyridin-3-yl-1,8-dihydro-9H imidazo[4,5-f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-1-methyl-1H imidazo[4,5 f]quinazoline-7,9-6H,8H
dione;
2-(2,6-Dichlorophenylamino)-1-methyl-7-propen-2-yl-1,8-dihydro-9H imidazo[4,5-f]quinazoline-9-one;
to 7-Cyclopent-1-enyl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H
imidazo[4,5-f Jquinazoline-9-one;
7-[2-(3 -Aminophenyl)-thiazol-4-yl]-2-(2, 6-dichlorophenylamino)-1-methyl-1, 8-dihydro-15 9H imidazo[4,5 f]quinazoline-9-one;
Ethyl 2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H -imidazo[4,5-f ] quinazoline-7-carboxylate;
2o 7-Benzofuran-2y1-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H
imidazo[4,5-fJquinazoline-9-one;
2-(2,6-Dichlorophenylamino)-1-methyl-7-(1-methylprop-1-enyl)-1,8-dihydro-9II
imidazo[4,5 f]quinazoline-9-one;
~-(2,6-Dichlorophenylamino)-1-methyl-7-(~.-methyloxazol-5-yl)-1,8-dihydro-9H
imidazo[4,5 f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-7-(1H indole-3-carbonyl)-1-methyl-1,8-dihydro-9H
3o imidazo[4,5 f]quinazoline-9-one;

2-(2, 6-Dichlorophenylamino)-1-methyl-7-(3 -piperazin-1-yl-cyclopent-1-enyl)-1, 8-dihydro-9H imidazo[4,5 f]quinazoline-9-one;
7-Cyclohex-1-enyl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H
imidazo[4,5-f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-1-methyl-7-(1-methyl-1,2,5,6-tetrahydro-pyridin-3-yl)-1,8-dihydro-9H imidazo[4,5 f]quinazoline-9-one;
2-(2, 6-Dichlorophenylamino)-1-methyl-7-[5-(2-nitrophenyl)-furan-2-yl]-1, 8-dihydro-9H
to imidazo[4,5 f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-7-furan-3-yl-1-methyl-1,8-dihydro-9H imidazo[4,5-f]quinazoline-9-one;
15 7-(5-Bromofuran-2-yl)-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H
imidazo[4,5 f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-methylfuran-2-yl)-1,8-dihydro-9H
imidazo [4, 5 f ] quinazoline-9-one;
7-Cyclopropyl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H imidazo[4,5-f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-1-methyl-7-[3-(4-methylpiperazine-1-sulfonyl)-phenyl]-1,8-dihydro-9H imidazo[4,5 f Jquinazoline-9-one;
4- f 3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H imidazo[4,5-f]quinazolin-7-yl]-cyclopent-2-enyl~-piperazine-1-carboxylic acid test-butyl ester;
2-(2,6-Dichlorophenylamino)-7-(3-hydroxycyclopent-1-enyl)-1-methyl-1,8-dihydro-imidazo[4,5 f]quinazoline-9-one;

2-(2, 6-Dichlorophenylamino)-1-methyl-7-[3-(piperazine-1-sulfonyl)-phenyl]-1, 8-dihydro-9H imidazo[4,5 f]quinazoline-9-one;
3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H imidazo[4,5-f ] quinazolin-7-yl]-cyclopent-3-enecarbonitrile;
7-Amino-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H imidazo[4,5-f]quinazoline-9-one;
l0 3- f 2-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8a dihydro-9H imidazo[4,5-f]quinazolin-7-yl]-propenyl}-benzonitrile;
3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H imidazo[4,5-15 f]quinazolin-7-yl]-cyclopent-3-enecarboxamide;
2- {4-[2-(2, 6-Dichlorophenylamino)-1-methyl-9-oxo-1, 8,-dihydro-9H -imidazo [4, 5-f]quinazolin-7-yl]-thiazol-2-yl~-pyrrolidine-1-carboxylic acid benzyl ester;
2o 2-(2,6-Dichlorophenylamino)-1-methyl-7-[1-methyl-2-(3-nitrophenyl)-vinyl]-1,8-dihydro-9H imidazo[4,5 f]quinazoline-9-one;
3- {4-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H -imidazo[4,5-f]quinazolin-7-yl]-thiazol-2-ylmethyl~-piperidine-1-carboxylic acid benzyl ester;
7-[2-(2-Aminocyclohexyl)-thiazol-4-yl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H imidazo[4,5 f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-piperidin-3-ylmethyl-thiazol-4-yl)-1,8-3o dihydro-9H imidazo[4,5 f]quinazoline-9-one;

2-(2, 6-Dichlorophenylamino)-1-methyl-7-(2-methylthiazol-4-yl)-1, 8-dihydro-9H
imidazo[4,5 f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-oxocyclopent-1-enyl)-1,8-dihydro-9H
imidazo[4,5 fJquinazoline-9-one;
3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H imidazo[4,5-f]quinazolin-7-yl]-2,5-dihydro-pyrrole-1-carboxylic acid tent-butyl ester;
l0 7-[2-(3-Aminophenyl)-1-methylvinyl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H imidazo[4,5 f]quinazoline-9-one;
Acetic acid 2-(4-~3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-imidazo[4,5 f]quinazolin-7-yl]- benzenesulfonyl~-piperazin-1-yl)-2-oxoethyl ester;
2-(2,6-Dichlorophenylamino)- 7-(2,5-dihydro-1H pyrrol-3-yl)-1-methyl-1,8-dihydro-9H
imidazo[4,5 f]quinazoline-9-one;
7-[2-(3-Aminomethylphenyl)-1-methylvinyl]-2-(2, 6-dichlorophenylamino)-1-methyl-1, 8-2o dihydro-9HHimidazo[4,5 f Jquinazoline-9-one;
4- f 3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H imidazo[4,5-f]quinazolin-7-yl]-benzenesulfonyl~-piperazine-1-carboxamidine;
2-(2,6-Dichlorophenylamino)-7-~3-[4-(2-hydroxyacetyl)-piperazine-1-sulfonyl]-phenyl}-1-methyl-1,8-dihydro-9H imidazo[4,5 f]quinazoline-9-one;
3- f 2-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H imidazo[4,5-f ]quinazolin-7-yl]-propenyl}-benzamidine;

7-(7-Azabicyclo [2.2.1 ]hepta-2, 5-dien-2-yl)-2-(2, 6-dichlorophenylamino)-1-methyl-1, 8-dihydro-9H imidazo[4,5 f]quinazoline-9-one;
5-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H imidazo[4,5-f]quinazolin-7-yl]-3,3a,4,6a-tetrahydro-1H cyclopenta[c]pyrrole-2-carboxylic acid tert-butyl ester;
2-(2,6-Dichlorophenylamino)-7-( 1,2,3,3 a,4,6a-hexahydro-cyclopenta[c]pyrrol-5-yl)-1-methyl-1,8-dihydro-9H imidazo[4,5 f]quinazoline-9-one;
2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-pyrrolidin-2yl-thiazol-4-yl)-1,8-dihydro-9H
imidazo[4,5 f]quinazoline-9-one;
7-[2-(3, 5-Diaminophenyl)-1-methylvinyl]-2-(2,6-dichlorophenylamino)-1-methyl-1, 8-dihydro-9H imidazo[4,5 f]quinazoline-9-one; and 2-(2, 6-Dichlorophenylamino)-1-methyl-7-[4-(piperazine-1-sulfonyl)-phenyl]-1, 8-dihydro-9H imidazo[4,5 f]quinazoline-9-one; and 2o the pharmacuetically acceptable derivatives thereof.
Any compounds of this invention containing one or more asymmetric carbon atoms may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention. Each stereogenic carbon may be in the R or S
configuration, or a combination of configurations.
Some of the compounds of the invention can exist in more than one tautomeric form. The invention includes all such tautomers.

The compounds of the invention are only those which are contemplated to be 'chemically stable' as will be appreciated by those skilled in the art. For example, a compound which would have a 'dangling valency', or a 'carbanion' are not compounds contemplated by the invention.
All terms as used herein in this specification, unless otherwise stated, shall be understood in their ordinary meaning as known in the art. For example, "C1_6alkoxy" is a Ci_6alkyl with a terminal oxygen, such as methoxy, ethoxy, propoxy, pentoxy and hexoxy.
All alkyl, 1o alkylene or alkynyl groups shall be understood as being branched or unbranched unless otherwise specified. Other more specific definitions are as follows:
The term "halogen" as used in the present specification shall be understood to mean bromine, chlorine, fluorine or iodine.
The term "heteroaryl" refers to a stable 5-8 membered (but preferably, 5 or 6 membered) monocyclic or 8-11 membered bicyclic aromatic heterocycle radical. Each heterocycle consists of carbon atoms and from 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulfur. The heterocycle may be attached by any atom of the cycle, which results in the creation of a stable structure. Example "heteroaryl" radicals include, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl, benzothiazolyl, quinazolinyl and indazolyl,or a fused heteroaryl such as cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline, cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline, cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole, 3o cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole, cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and cyclohexanothiophene;
The term "heterocycle" refers to a stable 5-8 membered (but preferably, 5 or 6 membered) monocyclic or 8-11 membered bicyclic heterocycle radical which may be either saturated or unsaturated, and is non-aromatic. Each heterocycle consists of carbon atoms and from 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulfur. The heterocycle may be attached to the main structure by any atom of the cycle, which results in the creation of a stable structure. Example "heterocycle" radicals include pyrrolinyl, pyrrolidinyl, to pyrazolinyl, pyrazolidinyl, 1,2,5,6-tetrahydropyridinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl, indolinyl, and 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl.
As used herein and throughout this specification, the terms "nitrogen" and "sulfur" and 15 their respective elements symbols include any oxidized form of nitrogen and sulfur and the quaternized form of any basic nitrogen.
The term "aryl" shall be understood to mean a 6-10 membered aromatic carbocycle, "aryl"
includes, for example, phenyl and naphthyl; other terms comprising "aryl" will have the 20 same definition for the aryl component, examples of these moieties include:
arylalkyl, aryloxy or arylthio.
The term "carbocycle" shall be understood to mean a 3-10 membered aromatic or nonaromatic cyclic carbon chain. Examples of nonaromatic carbocycles include cycloalkyl 25 groups such as cyclopropyl, cyclobutyl, cyclopentyl; cycloalkylidene groups such as cyclopentylidene, cyclohexylidene; and cycloalkenyl groups such as cyclopentenyl, cyclohexenyl and cycloheptenyl. Examples of aromatic carbocycles include the "aryl"
compounds as described hereinabove.
30 The "C6_12 bridged- or spiro-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 3 carbon atoms in the ring system may be replaced by heteroatoms selected from N, O and S" in the R5 definition shall be understood to mean any ring system containing 6 to 12 carbon atoms and having at least one bridged-type or spiro-type fusion within the ring system, wherein up to 3 of the aforementioned carbon atoms may optionally be replaced by a heteroatom independently selected from N, O and S. An example is a C6_io-, preferably, C6_~- bridged-bicyclic ring system, optionally having one or two double bonds in the system, wherein up to 2, preferably up to 1, carbon atoms in the ring system are replaced by a nitrogen atom. An example of such a ring system is 7-azabicyclo[2.2.1]hept-2,5-dime. Other examples within the broad definition include norbornenyl, tropanyl, 1-azabicyclo[2.2.2]oct-2-enyl, 7-azabicyclo[3.2.1]oct-6-to enyl, spiro[4.5]dec-1-enyl, and spiro[4.4]non-1-enyl.
The term "acyl" shall be understood to mean an R-(C=O)- moiety wherein R is an alkyl.
Examples of R can be a C1_ioallcyl, saturated or unsaturated, branched or unbranched, or R
can be "aryl" as defined hereinabove. An example when R is an aryl is the benzoyl group or C6H5-CO. "Acyloxy" shall be understood to mean an R-CO2- group wherein R is as defined in this paragraph.
As indicated above, one or more of the primary amine or secondary amine nitrogen atoms in any of the R4, Rj, R6 and R7 substituent groups may optionally be protected by a 2o protecting group. Suitable protecting groups for this purpose, for example, are those disclosed in T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", Wiley, New York, 1990. Examples of suitable protecting groups fox this purpose include benzyloxycarbonyl, tert-butyloxycarbonyl, allyloxycarbonyl, acetyl and trifluoroacetyl.
The invention includes pharmaceutically acceptable derivatives of compounds of the invention. A "pharmaceutically acceptable derivative" refers to any pharmaceutically acceptable salt or ester of a compound of this invention, or any other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound of this invention, a pharmacologically active metabolite or pharmacologically active residue thereof.

Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
Examples of suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, malefic, phosphoric, glycolic, lactic, salicylic, succinfic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids. Other acids, such as oxalic acid, while not themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of this invention and their pharmaceutically acceptable acid addition salts. Salts derived from appropriate bases include alkali metal to (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(Cl-C4 alkyl)4+
salts.
In addition, the compounds of this invention include prodrugs of compounds of the invention. Prodrugs include those compounds that, upon simple chemical transformation, 15 are modified to produce a compound of the invention. Simple chemical transformations include hydrolysis, oxidation and reduction, enzymatically, metabolically or otherwise.
Specifically, when a prodrug of this invention is administered to a patient, the prodrug may be transformed into a compound of the invention, thereby imparting the desired pharmacological effect.
General S~~nthetic Methods The compounds of the invention may be prepared by the methods described below.
In each of the schemes below, the groups R4, R5, Rb, R7, R9 and Ari are as defined above for general formula I except as noted. Optimum reaction conditions and reaction times may vary depending on the particular reactants used. Unless otherwise specified, solvents, temperatures, pressures and other reaction conditions may be readily selected by one of ordinary skill in the art. Specific procedures are provided in the Synthetic Examples section. Typically, reaction progress may be monitored by thin layer chromatography (TLC) if desired. Intermediates and products may be purified by chromatography on silica gel and/or recrystallization. Starting materials and reagents are either commercially available or may be prepared by one skilled in the art using methods described in the chemical literature.
Compounds of formula (I) in which Het is the dione shown in formula (Ia) (Scheme 1) may be prepared as illustrated in Scheme 1 and described below (Method A).
Scheme 1 (Method A) **
RCHO / I 1 ) NaNCO, / nitration H2N / CI Na.~ R~N \ CI acid _ R4'N ~ ~ CI
H 2) base ~ ~
O OH O OH Oi 'NI 'O
H
II Ila (R4 = RCHZ) III
/ NOz NO~ NHz / /
R ~ RNH ~ reduction I Ar~NCS
CI ~ R4'N ~ NHR R4'N ~ NHR
O H O O' _H O O' _H O
IV V VI
H H
/ ~ N~N~Ar~
I' N
R4'N ~ NHR cYclization ~ R4'N ~ N~H
~ ~ R
O"H O O' _H O
VII la ** preliminary step I I ~ I la for when R4 is not H
6-Chloroanthranilic acid (II) is reacted with sodium cyanate in the presence of a suitable acid, such as acetic acid, followed by a suitable base such as sodium hydroxide. Following an acidic work-up, the quinazolinedione III is isolated. In cases where R4 is not H, one may react II (R4 = H) with an appropriate aldehyde (RCHO) in the presence of a suitable l0 reducing agent, such as sodium borohydride to provide IIa (R4= RCH2).
Intermediate III is then subjected to nitration conditions, for example treatment with nitric acid in the presence of sulfuric acid to provide IV. Intermediate IV is then treated with excess amine RNHa (R = H, Cl-3 alkyl or cyclopropyl) in a suitable solvent, such as n-i5 butanol, preferably in a sealed vessel with heating at about 50 to 150° C, to provide V.

Reduction of V, for example by treatment with hydrogen preferably at 10 - 60 psi in the presence of a suitable catalyst such as 10 % Pd/c, provides VI. Treatment of VI with the desired isothiocyanate (ArINCS), in a suitable solvent such as DMF provides thiourea (VII). Cyclization of VII may be accomplished by treatment with a suitable coupling reagent, such as dicyclohexylcarbodiimide or mercury oxide in a suitable solvent such as THF or DMF to provide the desired compound Ia.
Compounds of formula (I) in which Het is substituted with RS as shown in formula (Ib) (Scheme 2) may be prepared as illustrated in Scheme 2 and described below (Method B).
to Scheme 2 (Method B) 1 ) RSCOCI
H N \ CI 2) base z O NHZ
IX NOa ~ nitration \ ~ triazine N \ ~ CI ~ N \ CI
HzN ~ ~CI ---~ I I
O OH tRs-H) RS~~ 0 R~~ 0 VIII X
NO2 / NHa / N ~r~
RNH~ I reduction I 1) Ar~NCS I ~> ~H( \ ~ \ -~ \
NHR ~ NHR 2) cyclization R5 ~ O R5 ~ O R5 ~ O
XI XIl Ib In cases where RS is H, one may treat 6-chloroanthranilic acid (II) with triazine in a suitable solvent, such as EtOH, in the presence of a suitable base such as piperidine, 15 preferably while heating at about the reflux temperature of the solvent to provide the quinazolinone VIII (RS = H). to obtain compounds where RS is not H, one may react the amide IX with an acid chloride RS LOCI, in a suitable solvent, such as THF, in the presence of a suitable base, such as triethylamine to provide an intermediate amide which is cyclized to VIII by treatment with a suitable base, for example sodium methoxide in 2o methanol, preferably at reflux temperature. Intermediate VIII may then be converted to Ib by the same general procedure described in Method A for a converting III to Ia.

The preparation of benzimidazole intermediates, which may be used in alternate procedures to prepare compounds of formula (I) is illustrated in Scheme 3 and described below (Method C):
Scheme 3 (Method C) / NOz RNH / NOZ / NOZ

CI ~ CI CI \ NH ~ R4~H ~ NH
CN CN R CN R
XIII XIV XV
H H
reduction / ~ NH2 Ar~NCS / I N~N~Ar~ cyclization R4~N \ NH ' R4~N \ NHIIS
H CN R H CN R
XVI XVII
/ N Ari / \ NAr~
R I \~H hydrolysis R \ ~ I ~H
4 W ~ ~,. 4 N
H CN R H R
O NHS
XVIII XIX
2,6-Dichloro-3-nitrobenzonitrile (XIII) is treated with the desired amine RNH2 (R = H, C1_3 alkyl or cyclopropyl) in a suitable solvent such as THF or EtOAc to provide XIV. This intermediate is then treated with R4NH2 in a suitable solvent such as EtOH, preferably in a sealed vessel while heating at about 50-110° C to provide XV. Reduction to ~VI, formation of thiourea XVII and cyclization to benzimidazole XVIII may be carried out as described for the conversion of V to Ia in Method A. Hydrolysis of the nitrile, fox example, by treatment with concentrated HaS04 at about 100° C, provides XIX.
is Method D (Scheme 4) illustrates how one may prepare compounds of formula (Ib) from intermediate XVIII (R4 = H).

Scheme 4 (Method D) / N Are O / N Are \ ~ hydrolysis ~N I ~N -R ~N \ N H R5 N \ N H cyclization H CN R H CN R
XVIII (Ra=H) XX
I N~ Ar N ~ N H
R

Ib Treatment of XVIII (R4 = H) with an acid halide RSCOX (where X is a halogen) or acid anhydride (RSCO)20 or with an acid RSCO~H and a coupling reagent such as dicyclohexylcarbodiimide or 1-[3-(dimethylamino)propyl)-3-ethylcarbodiimide, in a suitable solvent, such as THF or DMF, in the presence of a suitable base such as triethylamine or 4-(dimethylamino)pyridine provides amide ~X.
Hydrolysis of the nitrite, followed by cyclization to Ib may be achieved, for example, by treatment of ~X with a suitable base, such as aqueous sodium hydroxide, and an oxidant to such as hydrogen peroxide or sodium perborate in a suitable solvent such as dioxane.
Intermediate XIX (R4 = H) may be used to prepare compounds of formula (Ib) as outlined in Scheme 5 (Method E):

Scheme 5 (Method E) / N Are O / N Are ~- ~- N
R4w \ ( f H ~ \ I N' H
N ,N R5 N _ v H R H R

XIX (R4 = H) XXI
/ N~ Are base ' N
-.~ \ I N H
N
R
R~N O
H
Ib Formation of XXI may be accomplished as described above for conversion of XVIII to XX. Intermediate XXI may then by cyclized by treatment with a suitable base such as sodium methoxide or potassium t-butoxide in a suitable solvent such as MeOH or THF, respectively, at about reflux temperature to provide Ib.
Intermediate XIX may also be used to prepare compounds of formula (Ia) as illustrated in Scheme 6 (Method F).
Scheme 6 (Method F) / ~~-- NAr~ CDI / I ~~NAr~
R4w \ I N' H ~ R4~ N \ N~---H
or R phosgene R
O NH2 equivalent O H O
XIX la Treatment of XIX with carbonyldiimidazole (CDI) or a phosgene equivalent in a suitable solvent such as THF provides Ia.

Compounds of formula (I) in which Het is partially saturated may be prepared from intermediate XIX, as illustrated in Scheme 7 (Method G).
Scheme 7 (Method G) O
/ N
/ ~ ~Ari R~R' R ~ \' H
R4w ~ ~ N~NH 4~N ~ N
v acid ' R ~ R
R 6~ N O
O NHZ R~ H
XIX Ic (R6 and R~ are not H) / ~ N~NAra / N~ Are R = H R CHO ~ H I N
a a HN N oxidation N ~ N H
acid ~ R
R
R5 H H O Re H O
Id Ib Treatment of XIX with a ketone (R.6C(O)R~, where R6 and R7 are not H) in the presence of a catalytic amount of an acid such as p-TsOH, in a suitable solvent such as THF provides Ic (Rg and R7 are not H). When R4 = H, the use of an aldehyde (RSCHO) instead of a ketone provides Id. This compound may be oxidized to Ib by treatment with a suitable oxidizing agent such as Mn02 or dichlorodicyanobenzoquinone.
1o Compounds of formula (Ib) where RS = NHR9, represented by formula (Ib') below, may be prepared from intermediate XIX (where R4 = H) by Method H as illustrated in Scheme 8.

Scheme 8 (Method H) N Are / N Are \~N R9NCS S I \~N
R4.~N \ N H R9~N~N \ N H
H R H H

XIX XXII
N~ Are \ N
cyclization H
N

Ib' Reaction of XIX with an isothiocyanate in a suitable solvent such as DMF or THF
provides thiourea XXII. Cyclization or XXII may be accomplished by the addition of a suitable condensing agent such as mercury oxide to produce the desired product of formula (Ib') Scheme 9 (Method I) illustrates a procedure by which compounds of formula (I) with X = S may be prepared. Intermediate ~YV may be prepared from XXIII by reaction with l0 an acid chloride (RSC(O)Cl) to form an intermediate amide, followed by cyclization by treating with a suitable base such as sodium methoxide. Alternatively, if RS =
H one may react XXIV with triazine in a suitable solvent such as EtOH, in the presence of a suitable base such as piperidine to produce XXV (R$=H). Reduction of the nitro group to give XXVI and formation of thiourea XXVII may be accomplished by procedures described in 15 the above Methods. Cyclization of XXVII to give I (X = S) may be achieved by treatment with bromine in a suitable solvent such as CHC13.

Scheme 9 (Method I) / NOZ
1 ) RSCOCI
HEN \ ~ se / N02 / NH2 ~ Ari NCS
O' _NH2 N \ reduction N
XXIII
NO Rs H O Rs H O
XXV
XXVI
HZN ~ tnazme (R5 H) O OH
XXIV
/ N~NwAr / N Are ~~--N
N \ ~ S Brz N ~' S H
Rs~N O Rs/ 'N O
H H
XXVII I (X = S) Several of these transformations are also exemplified below.
Methods of Therapeutic Use The compounds of the invention are useful in inhibiting the activity of src-family kinases l0 and PDGFR kinase. In doing so, the compounds are effective in blocking disease processes mediated by these kinases. For example, by inhibiting p56 lck, the compounds block downstream signaling events following T cell activation by antigen. Activation of antigen-specific T cells is necessary for the induction and progression of diseases, including autoimmune diseases, allergic diseases and transplant rejection (J.H. Hanke et al., Ihflamm.
15 Res., 1995, 44, 357). Therefore the compounds of the invention are useful for treating such diseases. These include but are not limited to rheumatoid arthritis, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, psoriasis, graft versus host disease, systemic lupus erythematosus, insulin-dependent diabetes mellitus and asthma.
In view of their inhibitory effect on src-family kinases and PDGFR kinase, the compound of the invention are useful in treating cancer. For example, the compounds of the invention are useful in treating src-dependent tumors, such as in mammary carcinoma, colon carcinoma, melanoma and sarcoma, and are also useful in treating PDGF-dependent tumors, such as ovarian cancer, prostate cancer and glioblastoma. . In view of their inhibitory effect on src kinase, the compounds of the invention are also useful in treating 1o conditions involving cerebral ischemia, for example, in reducing brain damage following a stroke.
By inhibiting p60src, compounds of the invention may also be useful in treating osteoporosis, Paget's disease, bone inflammation and joint inflammation . By inhibiting PDGFR kinase, compounds of the invention may also be useful in treating fibrotic diseases, restenosis and atherosclerosis. By inhibiting lyn kinase, the compounds of the invention may also be useful in enhancing or potentiating the effectiveness of radiation therapy.
For therapeutic use, the compounds of the invention may be administered in any conventional dosage form in any conventional manner. Routes of administration include, but are not limited to, intravenously, intramuscularly, subcutaneously, intrasynovially, by infusion, sublingually, transdermally, orally, rectally, topically or by inhalation. The preferred modes of administration are oral and intravenous. Compositions comprising the compounds of the invention for each of the aforementioned routes of administration will be apparent to the skilled artisan. For example, one embodiment of the invention provides for pharmaceutical compositions including a therapeutically effective amount of the a compounds according to the invention. Such pharmaceutical compositions will include 3o pharmaceutically acceptable carriers,and adjuvants as further described below.

The compounds of this invention may be administered alone or in combination with adjuvants that enhance stability of the inhibitors, facilitate administration of pharmaceutic compositions containing them in certain embodiments, provide increased dissolution or dispersion, increase inhibitory activity, provide adjunct therapy, and the like, including other active ingredients. Advantageously, such combination therapies utilize lower dosages of the conventional therapeutics, thus avoiding possible toxicity and adverse side effects incurred when those agents are used as monotherapies. Compounds of the invention may be physically combined with the conventional therapeutics or other adjuvants into a single pharmaceutical composition. Advantageously, the compounds may to then be administered together in a single dosage form. In some embodiments, the pharmaceutical compositions comprising such combinations of compounds contain at least about 5%, but more preferably at least about 20%, of a compound of formula (I) (w/w) or a combination thereof. The optimum percentage (w/w) of a compound of formula(I) may vary and is within the purview of those skilled in the art. Alternatively, the compounds may be administered separately (either serially or in parallel). Separate dosing allows for greater flexibility in the dosing regime.
As mentioned above, dosage forms of the compounds of this invention include pharmaceutically acceptable carriers and adjuvants known to those of ordinary skill in the 2o art. These carriers and adjuvants include, for example, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, buffer substances, water, salts or electrolytes and cellulose-based substances. Preferred dosage forms include, tablet, capsule, caplet, liquid, solution, suspension, emulsion, lozenges, syrup, reconstitutable powder, granule, suppository and transdermal patch. Methods for preparing such dosage forms are known (see, for example, H.C. Ansel and N.G. Popovish, Pharmaceutical Dosage Foams and Drug Delivery Systems, 5th ed., Lea and Febiger (1990)). Dosage levels and requirements are well-recognized in the art and may be selected by those of ordinary skill in the art from available methods and techniques suitable for a particular patient. In some embodiments, dosage levels range from about 1-1000 mg/dose for a 70 kg patient. Although one dose per day may be sufficient, up to 5 doses per day may be given. For oral doses, up to 2000 mg/day may be required. As the skilled artisan will appreciate, lower or higher doses may be required depending on particular factors. For instance, specific dosage and treatment regimens will depend on factors such as the patient's general health profile, the severity and course of the patient's disorder or disposition thereto, and the judgment of the treating physician.
~Tnthetic Examples Example 1: Synthesis of 2-(2,6-Dichlorophenylamino)-1H imidazo[4,5 f]quinazoline-7,9(6H,81~-dione.
to 1. NaNCO ~ 90°lo HN03, ~ NOZ
2. NaOH ~ _ H2N ~ CI ~ HN ~ CI H2 HN 'CI
HOI 'O' 0i' "'O 0i' ' \O
CI
NOZ ~ NHZ SCN
NH3, n-BuOH HN I ~ NH Hz' Fd~C HN ~ NHZ CI

O ~ O O ~ O
CI CI
b DCC, THF ~ / ~>--~ CI
~NHz CI
O ~ O O ~ O
To a solution of 6-chloroanthranilic acid (1.72 g, 10 mmol) and NaOH (0.40 g, 10 mmol) 15 in water (15 mL) was added sodium cyanate (0.72 g, 11 mmol), followed by acetic acid (0.66 g, 11 mmol). The solution was stirred for 9 h, and then acidified with conc. HCI.
The precipitate was filtered off and washed with water. The wet solid was added to a solution of NaOH (8.0 g, 200 mmol) in water (60 mL) and stirred for 20 h. The precipitate was filtered off and suspended in water (80 mL), then heated to boiling and acidified with 50% HaSO4. The cooled mixture was filtered, the solid washed well with water and dried to give 5-chloroquinazolin-2,4-dione (1.42 g, 72%).
A solution of the above quinazolinedione (0.98 g, 5.0 mmol) in conc. H2S04 (5 mL) was cooled to -10 °C, and 90% HN03 (0.35 g, 5.0 mmol) was added with stirring. Stirring continued for 1 h at -10 °C, and 1.5 h at room temperature. The mixture was poured onto ice, filtered, washed with water and dried to give 5-chloro-6-nitroquinazolin-2,4-dione, to along with some of the 8-nitro isomer (1.3g, 94%).
Butanol ( 10 mL) was saturated with ammonia and placed in a sealed tube with the above compound ( 1.0 g, 4.1 mmol). The tube was heated to 125 °C for 3 h, then cooled. The solid was collected, washed with water, then ether, and dried to give 5-amino-nitroquinazolin-2,4-dione (0.82 g, 89%).
A suspension of the above amine (450 mg, 2.0 mmol) in DMF (15 mL) was hydrogenated over 10% Pd/C (60 mg) at 50 psi for 20 h. The catalyst was removed by filtration and the solvent removed to give 5,6-diaminoquinazolin-2,4-dione (369 mg, 95%) as a dark solid.
2o A mixture of the above diamine (342 mg, 1.78 mmol) and 2,6-dichlorophenyl-isothiocyanate (400 mg, 1.96 mmol) in DMF was stirred for 17 h. The solvent was removed and the residue triturated with EtOAc to give the thiourea. A portion of the thiourea (200 mg, 0.51 mmol) was dissolved in DMF (2 mL) and a solution of dicyclohexylcarbodiimide (125 mg, 0.61 mmol) in THF (4 mL) was added. The mixture was heated to 80 °C under reflux for 7 h, and the solvent removed. The residue was dissolved in CHZCl2/THF/TFA (150:50:1) and filtered though a plug of silica.
The filtrate was evaporated, the residue triturated twice with THF, and the supernatant pipetted off.
The solid was suspended in MeOH, neutralized with NH4OH, and the product collected by centrifugation to give the title compound, 1 (89mg). Mp >300 °C.

Example 2: Synthesis of 2-(2,6-Dichlorophenylamino)-6-methyl-1H imidazo[4,5-f ] quinazoline-7,9(6H,8H)-dione.
c1 ~_ H C. I / ~H CI

O N O
H

Sodium (3.35 g, 146 mmol) was slowly added to stirred MeOH (45 mL). Upon completion of gas evolution, 6-chloroanthranilic acid (5 g, 29 mmol) was added forming a suspension.
This mixture was added to a separate flask containing a suspension of paraformaldehyde (1.22 g, 43.5 mmol) in MeOH (35 mL), and the resulting solution was stirred for 5 h at l0 room temperature. Sodium borohydride (1.1g, 29 mmol) was added and the mixture refluxed for 3h. The cooled mixture was hydrolyzed with 1 M potassium hydroxide then neutralized to pH 3 using 2 M HCI. The precipitate was filtered to yield 2-chloro-6-methylamino benzoic acid (2.2 g, 41 %).
2-Chloro-6-methylamino benzoic acid was converted to 5-amino-1-methyl-6-nitroquinazolin-2,4-dione by the three step procedure described in Example 1.
A suspension of 5-amino-1-methyl-6-nitroquinazolin-2,4-dione (400 mg, 1.64 mmol) in MeOH (70 mL) was hydrogenated over 10% Pd/C (150mg) in a Parr shaker at 50 psi until uptake ceased. The catalyst was removed by filtration and the filtrate concentrated to yield 5,6-diamino-1-methylquinazolin-2,4-dione (350 mg, 99% crude).
A solution of the above diamine (350 mg, 1.69 mmol) and 2,6-dichlorophenylisothiocyanate (381 mg, 1.88 mmol) in DMF (15 mL) was stirred under nitrogen for 72 hr. The solvent was evaporated and the residue triturated with ethyl acetate to yield the thiourea (430 mg, 62%). A portion of the thiourea (300 mg, 0.73 mmol) was dissolved in DMF (3 mL) and a solution of dicyclohexylcarbodiimide (166 mg, 0.8 mmol) in THF (6 mL) was added. The mixture was stirred at 80 °C for 4 h. The solvent was removed, and the residue crystallized twice from MeOH to yield the title compound, 2 (65mg, 24%). Mp >300 °C.
Example 3: Synthesis of 2-(2,6-Dichlorophenylamino)-1,8-dihydro-9H imidazo[4,5-f ] quinazoline-9-one.

s-triazine ~ 90% HN03, H N I ~ CI EtO~ N I / CI H~~ N I ~ Cl HO O 'N O 'N O
H H
CI
NO~ I ~ NHz SCN
NH3, ~ / H2, PdIC
n-BuOH_ ~ NHZ ~ ~ ~ ~NHZ CI ~
H O H O
H H CI CI
N S N I , DCC, THF I , N~--N CI
NH2 CI ~ ~ H H
H O H O

A solution of 6-chloro anthranilic acid (2.12 g, 12.3 mmol) and triazine (1.0 g, 12.3 mmol) in EtOH (40 mL) containing piperidine (3 drops) was heated under reflux with stirring for 8 h. On cooling crystals formed, which were filtered to yield 5-chloroquinazolin-4-one (1.55 g, 70%).
A solution of the above quinazolinone (1.26 g, 7.0 mmol) in conc. HZS04 (7 mL) was cooled to -20 °C, and 90% HN03 (0.49 g, 7.0 mmol) was added with stirring. Stirring continued for 1 h at -20 °C, and 2 h at room temperature. The mixture was poured onto ice, filtered, washed with water and dried to give 5-chloro-6-nitroquinazolin-4-one, along with the 8-nitro isomer in a 4:1 ratio. Three recrystallizations from EtOH gave the product as a 6:1 ratio of isomers (0.85g).
Butanol (20 mL) was saturated with ammonia and placed in a sealed tube with the above compound (800 mg, 3.6 mmol). The tube was heated to 125 °C for 14 h, then cooled.
The solid was collected, washed with EtOH and water, and dried to give 5-amino-nitroquinazolin-4-one (569 mg, 78%).
A suspension of the above amine (250 mg, 1.21 mmol) in MeOH (50 mL) was to hydrogenated over 10% Pd/C (50 mg) at 50 psi fox 5 h. The catalyst was removed by filtration and the filtrate concentrated to yield 5,6-diarninoquinazolin-4-one (210 mg, 98%
crude).
A solution of the above diamine (205 mg, 1.19 mmol) and 2,6-dichlorophenylisothiocyanate (272 mg, 1.3 mmol) in DMF (3 mL) was stirred under nitrogen for 18 h. The solvent was evaporated and the residue triturated with ethyl acetate to yield the thiourea (350 mg, 77%). The thiourea was dissolved in DMF (4 mL) and a solution of dicyclohexylcarbodiimide (228 mg, 1.1 mmol) in THF (8 mL) was added. The mixture was stirred at 80 °C for 8 h and the solvent evaporated. The residue was purified by column chromatography in CHZC12/MeOH 98:2 - 90:10. Pure fractions were combined, evaporated, and the residue recrystallized from MeOH to give the title compound, 3 (87 mg). mp 230-235 °C.
Example 4: Synthesis of 2-(2,6-Dichlorophenylamino)-1-methyl-1,8-dihydro-9H
imidazo[4,5 f]quinazoline-9-one.

CI
N
N I , N~--H CI
II CHs 'N O
H

5-Chloro-6-nitroquinazolin-4-one, from Example 3 (0.26 g, 1.15 mmol) was suspended in MeOH (3 mL) at -20 °C. Methylamine gas was passed into the mixture for a few minutes, resulting in a clear solution. The solution was stirred at room temperature for 5 h and evaporated to give 5-methylamino-6-nitroquinazolin-4-one in quantitative yield.
The above amine (350 mg, 1.6 mmol) was hydrogenated over platinum oxide (30 mg) in MeOH (200 mL) at 60 psi for 4 h. The mixture was filtered through diatomaceous earth and the solvent evaporated, to give 6-amino-5-methylaminoquinazolin-4-one, which was to immediately suspended in EtOAc (20 mL) and THF (10 mL). A solution of 2,6-dichlorophenylisothiocyanate (340 mg, 1.67 mmol) in EtOAc (5 mL) was added, and the mixture stirred for 16 h. The reaction mixture was concentrated to half the volume, filtered, and the solid washed with EtOAc to yield the thiourea (400 mg, 64%
over 2 steps.) A solution of the above thiourea (295 mg, 0.75 mmol) and dicyclohexylcarbodiimide (160 mg, 0.7~ mmol) in THF (12 mL) and DMF (10 mL) was heated to 70 °C with stirring for 4~ h. The mixture was poured into ice water (50 mL) and filtered. The filtrate was extracted with EtOAc and evaporated. The residue was combined with the filtered solid, 2o triturated with chloroform, and the supernatant decanted. The solid was dissolved in boiling MeOH (100 mL), filtered hot, concentrated to 60 mL, and water (10 mL) added slowly. The crystals were collected to give the title compound, 4 (110 mg, 41%). Mp >300 °C.
Example 5: Synthesis of 2-(2,6-Dichlorophenylamino)-1-ethyl-1,8-dihydro-9H
imidazo[4,5 f]quinazoline-9-one.

This compound was synthesized in by the method of Example 4. Mp >300 °C.
Examples 6 and 7 NOz MeNHz(aq) ~ NOz NH3, CI I / CI EtOAc 10~ CI I / N, EtON 90 °~
CN CN H
CI
SCN ~
NHz NOz Hz, PdlC I ~ CI
H N I / N~ THF ~ / i HgO, THF, re~lux HzN N
z CN H CN H
CI ~ ~ CI
N conc. HzS04 ~ N
I ~ yN CI 110 °~ I ~~N CI
HzN / \ H HaN ~ \ H
CN HZN O
AczO, THF PhCOCi DMAP Et3N, THF
CI ~ ~ CI ~
N O ~ N
I ~ ~>---N CI I ~~"N CI
N / N H ~ N ~ N H
H CN \ I / H \

urea-H20z NaOMe NaOH, dioxan 110~C MeOH, reflux CI ~ ~ CI ~
/ ~H CI I / ~H CI
O I ~ ~H O

Example 6: Synthesis of 2-{2,6-Dichlorophenylamino)-1,7-dimethyl-1,8-dihydro-imidazo[4,5 f]quinazoline-9-one.

A solution of 2,6-dichloro-3-nitrobenzonitrile (98.7 g, 0.455 mol) in EtOAc (910 mL) was cooled to 5°C. 40% Aqueous methylamine (79.5 mL, 1.14 mol) was added with vigorous mechanical stirring, keeping the temperature at 10-15°C. After addition was complete, stirring was continued for 3 h at the same temperature. More methylamine (16 mL, 0.23 mol) was added, and the mixture stirred for a further 1.5 h at room temperature. Water (300 mL) was added, followed by hexane (450 mL). The mixture was stirred for 15 min, filtered, and the solid washed with water and MeOH, to give 6-chloro-2-methylamino-3-nitrobenzonitrile (80.3 g, 83%), mp 167-170°C.
to A suspension of the above amine (30.0 g, 142 mmol) in a 5.3 M solution of ammonia in ethanol (200 mL) was heated in a sealed stainless steel reaction vessel (600 mL capacity) at 90 °C for 24 h. The reaction vessel was cooled to room temperature, then to 0°C, and opened. The product was filtered, washed with ethanol (30 mL) and dried to give 6-amino-2-methylamino-3-nitro-benzonitrile (25.94 g, 95%) as a yellow solid.
A solution of the above diamine (5.0 g, 26 mmol) in THF (150 mL) was hydrogenated over 10% PdIC (1.0g) at 50 psi for 4 h. The reaction mixture was filtered through a pad of diatomaceous earth and rinsed with THF (50 mL). The filtrate was not concentrated but 2o used crude as a THF solution.
To the above triamine solution was added 2,6-dichlorophenylisothiocyanate (5.3 g, 26 mmol) and the solution was stirred at room temperature for 0.5 hr. TLC
indicated complete formation of the thiourea intermediate. Mercury (II) oxide (6.2 g, 29 mmol) was then added, and the mixture was heated to reflux for 2h. TLC showed conversion to the benzimidazole. The reaction mixture was cooled to room temperature, activated carbon (about 1g) was added, and stirred at 50 °C for 2h. The mixture was filtered through a pad of diatomaceous earth and rinsed with EtOAc until the filtrate was colorless.
The combined filtrates were concentrated to obtain a pink solid, which was triturated with EtOAc/hexane (1:4). The light grey color solid was filtered and dried to give 5-amino-3-methyl-2-(2,6-dichlorophenylamino)-3H benzimidazole-4-carbonitrile (7.42 g). The mother liquor was concentrated and triturated again to provide a second crop (0.15 g), combined yield 87%, MS (EI+): MHk = 331.
To the above amino nitrite (60 mg, 0.18 mmol) in THF (1 mL) was added acetic anhydride (74 mg, 0.72 mmot) and DMAP ( 1 crystal), and the solution stirred for 22 h.
MeOH (0.5 mL) Was added, and stirring continued for 1 h. The solution was partitioned between EtOAc and dilute NH40H, and the residue from the organic layer purified by flash chromatography, eluting with CH2C1~1THF 95:5, to give recovered amino nitrite (18 mg) and 5-acetamido-3-methyl-2-(2,6-dichlorophenylamino)-3H benzimidazole-4-carbonitrite (47 mg).
A suspension of the above acetamide (30 mg, 0.08 mmol) in dioxan (1 mL) and 0.2M
NaOH (1 mL) was heated to 110 °C. Urea-hydrogen peroxide complex (15 mg, 0.16 mmol) was added with stirnng. Further 30 mg portions of urea-hydrogen peroxide were added at 2.5 h, 3.5 h and 21 h. After heating for 25 h, the mixture was cooled and partitioned between THF and water. The residue from the organic layer was purified on a flash column, eluting with CHZCl2/MeOH 98:2, to give the title compound, 6 (7 mg, 23%), mp 305-310 °C(dec), MS (ES) 374, 376 (MH+).
2o Example 7: Synthesis of 2-(2,6-Dichlorophenylamino)-1-methyl-7-phenyl-1,8-dihydro-9H imidazo[4,5-f]quinazoline-9-one.
A mixture of 5-amino-3-methyl-2-(2,6-dichtorophenylamino)-3H benzimidazole-4-carbonitrile (Example 6) (1 g, 3 mmot) and cons. H2S04 (8 mL) was warmed to °C for 1 h and monitored by TLC for the disappearance of starting material. The mixture was cooled and poured onto a mixture of crushed ice, sodium carbonate, and ether. The precipitate was filtered, washed with water, dissolved in MeOH-methylene chloride, treated with carbon (decotorizing charcoal), dried (MgS04), filtered, and concentrated in vacuo. The aqueous filtrate was washed with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (25 mL), which was then extracted with EtOAc (20mL).
The combined organic layers were dried (MgS04), filtered, and concentrated to yield 190 mg of a crude product. This was combined with the solid product and triturated with ether-methylene chloride to afford 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3H
benzoimidazole-4-carboxylic acid amide (700 mg, 66%). The filtrate was chromatographed on silica gel to afford an additional 128 mg (12%) of product.
The above amino amide (50 mg, 0.15 mmol) was added to a solution of benzoyl chloride (32 mg, 0.23 mmol) in THF (1 mL). Triethylamine (0.03 mL, 0.23 mmol) was added and the mixture stirred for 1 h. TLC showed conversion to the benzamide. The solvent was evaporated and the residue dissolved in MeOH (1 mL). Sodium methoxide in MeOH
to (25%, 0.2 mL) was added and the solution heated to reflux for 45 min. The cooled mixture was partitioned between 1M NH4C1 and CH2C12. The residue from the organic layer was stirred and refluxed with MeOH (2 mL) for 1 h, cooled, filtered and washed with MeOH to yield the title compound, 7 (52 mg, 79%) Mp >300 °C. MS (ES+) 436, 438 (MH+).
15 Example 8: Synthesis of 2-(2,6-Dichlorophenylamino)-1-methyl-7-furan-3-yl-1,8-dihydro-9H imidazo[4,5 f]quinazoline-9-one.
i N~-H ~ C
N
O

Furan-3-carboxylic acid (20 mg, 0.18 mmol), hydroxybenzotriazole (24 mg, 0.18 mmol) 2o and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (35 mg, 0.18 mmol) were stirred together in DMF (1 mL) for l5min. 5-Amino-2-(2,6-dichlorophenylamino)-3-methyl-3H benzoimidazole-4-carboxylic acid amide (Example 7)(50 mg, 0.15 mmol) was added, and stirring continued for 24 h. The solution was diluted with EtOAc and washed in turn with aqueous Na2C03, water and brine. The organic layer was evaporated and the 25 residue dissolved in MeOH (2 mL). Sodium methoxide in MeOH (25%, 0.1 mL) was added and the solution heated to reflux for 45 min. The cooled solution was partitioned between water and CHaCIa. The organic layer was evaporated and the crude product stirred with MeOH (1 mL) for 1 h. The solid was filtered, washed with a few drops of MeOH and dried to yield the title compound, 8 (14 mg, 22%). mp >300 °C. MS (ES) 428, 426 (MH+).
Example 9: Synthesis of 7-allylamino-2-(2,6-dichlorophenylamino)-1-methyl--1,8-dihydro-9H imidazo[4,5-fjquinazoline-9-one.
c1 ~
N
~>.-N CI AIIyINCS
HZN / N H H

HZN O
CI
N
HgO I ~>--N CI
N / N H
\ ~ CH3 ~N N O
H H

1o A mixture of 100 mg (0.286 mmol) of 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3H benzimidazole-4-carboxylic acid amide (Example 7) and 114 mg (1.15 mmol) of allyl isothiocyanate in DMF was warmed at 45 °C for 48 h. The reaction was diluted with 30 mL of brine and extracted with four 15 mL portions of EtOAc. The combined organic layers were washed with five 15 mL portions of brine, dried (MgS04), filtered and 15 concentrated in vacuo. The residue was adsorbed onto silica gel and chromatographed on silica gel (MeOH-methylene chloride, first 2:98, then 4:96, then 5:95) to afford 66 mg (51 %) of 2-(2,6-dichlorophenylamino)-3-methyl-5-(3-allyl-thioureido)-3H
benzimidazole-4-carboxylic acid amide.
2o A mixture of 66 mg (0.15 mmol) of the above amide and 300 mg (1.38 mmol) of mercury (II) oxide in THF was warmed at reflux for 1 ~ h. The reaction was cooled to room temperature and filtered through diatomaceous earth. The filtrate was adsorbed onto silica gel and chromatographed over silica gel (methylene chloride, then MeOH-methylene chloride, first 1:99, then 2:98, then 3:97) to afford an off white solid which was triturated with methylene chloride-MeOH to afford 17 mg (27%) of the title compound 9, mp 260 °C.
Example 10: Synthesis of N [2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H imidazo [4,5 f J quinazolin-7-yl]-benzamide.
CI ~ ~ CI ~
N~--N CI PhC(O)NCS N~-- N i CI
H N ~ N H N' H
z ~ v HzN O

To a solution of 128 mg (0.36 mmol) of 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3H-benzimidazole-4-carboxylic acid amide (Example 7) in 10 mL of THF was added mg (0.45 mmol) of benzoyl isothiocyanate. The reaction was warmed at reflux and after 5 min, thin-layer chromatography indicated a new product. 95 mg (0.44 mmol) of mercury (II) oxide was added and refluxing continued for 24 h. The reaction was cooled and filtered through diatomaceous earth washing the filter cake with EtOAc. The crude residue Was adsorbed onto silica gel and chromatographed over silica gel (MeOH-methylene chloride, first 1:99, then 2:98, then 3:97). The material from the column was triturated 2o with ether-dichloromethane to afford 64 mg (36%) of the title compound 10, mp, 185-190 °C.
Example 11: Synthesis of 7-amino-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H imidazo[4,5 fJquinazolin-9-one.

C
N
~>--N CI
~- N / N H

A mixture of 130 mg (0.27 mmol) 10 and 500 mg (3.62 mmol) of potassium carbonate in MeOH was stirred for 18 h. The mixture was then diluted with brine and extracted with EtOAc to afford 12 mg of product. Additional material was obtained as an insoluble solid from the extraction layers. The combined materials were dissolved in 1N
aqueous HCI, diluted with THF, made basic with solid/saturated aqueous sodium bicarbonate and extracted with EtOAc to afford 40 mg (40%) of product. Trituration with ether gave 30 mg (30%) of title compound 11, mp > 305 °C.
1o Example 12: Synthesis of 2-(2,6-Dichlorophenylamino)-1-methyl-7-(1-methyl-2-phenyl-vinyl)-1,6,7,8-tetrahydro-9H imidazo(4,5 f]quinazolin-9-one.
CI
c1 ~ ~ PncH=c(cH3>e N ~ CI
w y-cl H2N ~N

A mixture of 110 mg (0.315 mmol) of 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3H-benzimidazole-4-carboxylic acid amide, 184 mg (1.26 mmol) of a-methyl-t~aras-cinnamaldehyde and 60 mg (0.31 mmol) ofp-toluenesulfonic acid in 10 mL of THF
were _77_ stirred at RT for 18 h. The reaction was made basic with saturated aqueous sodium bicarbonate and extracted with EtOAc. The combined organic layers were washed with saturated aqueous sodium bicarbonate, brine, dried (MgS04), filtered and evaporated in vacuo. The crude residue was chromatographed on silica gel to afford 102 mg (68%) of title compound 12.
Example 13: Synthesis of 2-(2,6-Dichlorophenylamino)-1-methyl-7-(1-methyl-2-phenyl-vinyl)-1,8-dihydro-9H imidazo[4,5 f]quinazoline-9-one.
CI
N CI
Mn02 H

A mixture of 102 mg (0.213 mmol) 12 and 300 mg (3.45 mmol) of manganese dioxide was stirred in 15 mL of THF for 45 min. The reaction was filtered through diatomaceous earth and evaporated in vacuo. The crude residue was evaporated onto silica gel and chromatographed over silica gel (methylene chloride, then MeOH-methylene chloride first 1:99 then 2:98). The material from the column was triturated with MeOH-methylene chloride to afford 70 mg (69%) of title compound 13, mp > 305 °C.
Example 14: Synthesis of 2-(2,6-Dichlorophenylamino)-1-methyl-1H imidazo[4,5-f J guinazoline-7,9(6H,8H)-dione.
c1 ~ \ ~I / \
\ N>--N CI triphosgene I ~ ~~H CI
H2N ~ N H HN ~ N
CH3 ~ CH3 HzN O O H O

_78_ To a solution of 80 mg (0.229 mmol) of 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3H-benzimidazole-4-carboxylic acid amide (Example 7) in 8 mL THF cooled to 0 °C was added 67 mg (0.23 mmol) of triphosgene. After stirring 30 min, the reaction was diluted with saturated aqueous sodium bicarbonate and water, and the THF was evaporated in vacuo. The resulting suspension was filtered and the solid dried by pulling vacuum through the filter cake. The crude product was absorbed onto silica gel and chromatographed over silica gel (MeOH-methylene chloride first 1:99 then 2:98 then 3:97 then 4:96) to afford a solid which was triturated with methylene chloride to afford 20 mg (23%) of the title compound 14, mp > 300 °C.
l0 Example 15: Synthesis of 2-(2,6-Dichlorophenylamino)-1,7-dimethyl-1,6,7,8-tetrahydro-9H imidazo[4,5 fjquinazolin-9-one.
CI ~ ~ CI
~~--N CI CH CHO I \ ~~N CI
HN / N H HN / N H
CH3 ~ CH3 H2N O H3C ~ O
15 A mixture of 30 mg (0.086 mmol) of of 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3H-benzimidazole-4-carboxylic acid amide (Example 7) and 1 mL (18 mmol) of acetaldehyde was stirred under an argon atmosphere while chilled in an ice-water bath for 0.5 h, then warmed to room temperature. p-Toluenesulfonic acid was added, (catalytic) and after stirring for 1 h, 2 mL of MeOH was added. After 2 h the reaction was poured into a 2o mixture of saturated aqueous sodium bicarbonate and EtOAc. The aqueous layer was extracted with EtOAc, the combined organic layers were extracted with saturated aqueous sodium bicarbonate, brine, dried (MgSO4), treated with activated carbon, filtered, and concentrated in vacuo. The residue was chromatographed over silica gel, followed by elution on a TLC plate to yield 11 mg (34%) of title compound 15, mp 200-203 °C.

Example 16: Synthesis of 2-(2,6-Dichlorophenylamino)-1,7,7-trimethyl-1,6,7,8-tetrahydro-9H imidazo[4,5 f]quinazolin-9-one.
CI ~ ~ CI
\ N~--N CI acetone ~ \ ~~'N ~ CI
HzN / N H --~ HN / N H
CH3 H3C~ CH3 HzN O H C H O

A mixture of 38 mg (0.11 mmol) of 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-benzimidazole-4-carboxylic acid amide (Example 7), 3 mg (0.02 nunol) p-toluenesulfonic acid, and 2 mL (27 mmol) of acetone was stirred at room temperature for 1 h, then heated to reflux for 1.5 h. The reaction was cooled and poured into a mixture of saturated aqueous sodium bicarbonate and EtOAc. The aqueous phase was extracted with EtOAc, 1o the combined organics were extracted with saturated aqueous sodium bicarbonate, brine, dried (MgSO4), treated with activated carbon, filtered, and concentrated in vacuo to afford 26 mg of an orange solid. The crude product was chromatographed over silica gel to afford 20 mg (47%) of title compound 17, mp 238-239 °C.
15 Example 17: Synthesis of 2-(2,6-Dichlorophenylamino)-1,7-dimethyl-9-oxo-6,7,8,9-tetrahydro-1H imidazo[4,5 f]quinazoline-7-carboxylic acid ethyl ester.
CI ~ ~ CI
\ N \ N
/ N~H CI CH3C(O)COzEt I / N>--H CI
HzN ~ \ HN
CH3 H3C~ CH3 H2N O / 'N O
EtOzC H

A mixture of 100 mg (0.29 mmol) of 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3H-2o benzimidazole-4-carboxylic acid amide (Example 7), 332 mg (2.9 mmol) of ethyl pyruvate, and a catalytic amount ofp-toluenesulfonic acid in 2 mL of dichloromethane was heated in a sealed tube to 85 °C for 2 h, then 0.5 mL EtOH was added, and heating continued for 15 min. The reaction was cooled and stirred at room temperature for 1 h.
The reaction was concentrated in vacuo, and the residue was suspended in dilute aqueous sodium hydroxide, filtered, washed with water and dried by pulling vacuum through the filter cake. The crude product was purified on a TLC plate, and recrystallized from EtOAc to afford 17.6 mg (13.5%) of title compound 17, mp 245-247 °C.
Additional Examples l0 The following additional compounds (Ex. Nos. 18 to 104) in the following Table were prepared by methods analogous to those described above.
Ex.
No. Structure M. P.(°C) CI
N
CI
N N
18 I \ N O CH3 >300 H
~N~O_ CI \
N
CI
N N
19 I \ N O CH3 200 (dec) H

C
N
CI
N N
I
20 I \ N O CH3 251 (dec) H
O NH
/NH

CI
N
\ ~ H CI
N
_N
21 H2C \ I CH3 278-N O
H 284 (dec) CI
N
\ ~ ~H CI
N N
22 ~ I CH3 >300 O
CI
N
\ I H CI
CI N
o I
23 ~S ~N CH3 280 HsC O \ S H O
-~2-CI
N
CI
N N
24 S ~.~ ~N CH3 >300 N H O
NO~
CI
N
\ ~ >--H CI
N N
25 N~ N O CH3 >300 ~NH H
CI \
N
CI
N N
l 26 N \~~ ~H CH3 >290 O O

CI
N
\ ~ ~H CI
N
~N
27 ~ N O CH3 >300 CI
N
CH3 N \ ~ ~H CI
~N
>300 H
CI
N
\ ~ ~H CI
N N
29 I \ N O CH3 >300 rN H
CI
N
\ ~ ~H CI
N N
30 I \ N O CH3 >300 NJ H
CI \
N
/ N \ ~ >-H CI
w ~I

H

CI
N
F \ ~ >-H CI
F~F N
N I 'N
32 O / \ ~ \ N CH3 >300 N.,O H O
CI
N
\ ~ ~H CI
N N
33 H2C N O CH3 >300 CI
N
/ \ ~ ~ H CI
N
34 ~ N O CH3 >250 H
(dec) CI
N
\ ~ ~H CI
N N
I
35 w ~N CH3 295 (dec) H O

CI \
N
CI
N N

36 S ~ ~H ~ O CH3 240 (dec) ~N

CI
N
\ ~ ~H CI
N N
37 HsC\~C N O CH3 275-277 O H
CI
N
\ ~ N CI
CH3 ~ N H
I
38 ~ \ ~H O CH3 >300 CI
N
\ ~ ~--H CI
N N
39 / ~ N O CH3 >300 r C H

CI
N
\ ~ >--H CI
N

40 N CH3 258 (dec) H O
CI
N
\ ~ H CI
N
O I _N
41 ~N O CH3 265-268 NH H
HO
CI
N
CI
N
O ~ 'N
42 ~N CH3 >300 H O
OH
CI
N
CI
N
I 'N
43 N N O CH3 >300 H

CI ~ f N
\ ~ ~H CI
N N

~N H
CI \
N
CI
N N
45 H3C ~~~N O CH3 278 (dec) CI
N
CI
N N
46 N~ ~ N C CH3 >300 H

CI
N \ >--~ CI
HN ~ ~N
47 ~ N O CH3 >300 O H
_88_ CI ~ f N
CI
N N
48 H N ~. N O CH3 173-174 H
CI
N
CI
N N
49 H3C N O CH3 279 (dec) CI
i N
CI
N N
I
50 ~N O CH3 283-284 H
CI \
N
CI
N N
51 \ N O CH3 H
CI
N
\ ~ ~H CI
N
N
52 ~N CH3 295 (dec) O , H O
-~9-CI
N
\ I ~H CI
N
'N
53 H3C~ CH3 >300 N O
H
CI
N
\ I ~H CI
N
'N
54 ~ N O CH3 255 H
N
I

CI
N
N02 N \ I >---H CI
~N
55 ~ \ O N CH3 289-292 H O
CI
N
\ I ~H CI
N N
56 ~ N O CH3 >300 O ~ .H

CI
N
CI
N
~N
57 Br C N O CH3 280-283 H
CI
N
H3C N \ I ~H CI
~N
58 ~ N CH3 304-310 \ O H C (dec) CI
N
N \ I >---H CI
~N
59 ~ CH3 >300 N .O
H
Cl \
N
\ I ~--H CI
60 ~ ' I CH 280 (dec) w0 CI
N
N ~ I >--H CI
'N
61 ~ I CH3 215 (dec) I 'H O
O~S~O
N
N

CI
N
N ~ I ~-- \ CI
H C ~ ~N H
62 3 ~N CH3 198-204 O
H
Cl N
N ~ I >--H CI
'N
63 H3C I ~H3 >300 I H O
HsC CHs CI
N
N ~ I ~>----H CI
'N
64 H C ~ CH3 257-260 O
CI
N
I ~--H CI
O ~ I 'N
65 H C ~N N ~ N O CH3 168-170 U ~ H
/\ O
HsC CHs CI
N
N ~ I >--H CI
'N
66 HO ~ I CH3 285 N O
H

CI \
N
\ I ~--H CI
'N
67 \ ~ CH3 189 I .H O
O~S~O
N
N
~O CH3 O ~
/'CH3 CI \
N
N \ I ~--H CI
'N
68 \ I CH3 210 I .H O
O'S~ O
N
N
H

CI \
N
N \ I >--H CI
'N
69 \ I CH3 >295 H O (dec) N
CI
N
N \ I >--H CI
'N

I H O
I \
i CI \
N
\ I ~--H CI
'N

I H O
I \

CI
N
I >-H CI
'N
72 ~ I _ CH3 >215 H O (dec) O
CI
N
N ~ I CI
~'N
73 S ~ I CH3 209 H O
=N
H O
N
O
CI
N
N ~ I ~--H CI
'N
74 ~ ~ I N CH3 254-256 I ~ H O

-O~N~~O

O
75 O I ~ 163-169 NH N \ ~--H CI
~N
N
.,.... / I CHs '~ / N O
S H
O CI
76 ~O ~ N \ ' 155-160 N N \ I ~~---H CI
,N

I H O
S
CI
N
NH N \ ~ ~H CI
77 2 N I ' CH 295-300 ~N s S H O (dec) CI
~ N
N \ ~ ~H CI
'N
78 N f CH3 161-166 I .H O
S

CI
N
N ~ I >--H CI

S ~ N O CH3 295 (dec) \;N H
H3 j~C
CI
N
H~N~H N ~ I >-H CI
'N
80 ~ \ I _ CH3 310-313 I H O
CHa CI
N
N ~ I ~~--H CI
'N
81 O ~ I _ CH3 >300 N O
H
O O , Nl 82 I ~~-- N Cl >275 N N ~ ° H
' CH (dec) _H O s CI
N
N ~ I ~--H CI
~' N

s ~ N O
O H

CI
N
N .~ I ~-H CI

\ \ N CH3 >300 / CH H O (dec) Cl N
I ~H CI
N N
I
85 ~ \ ~H O CH3 246 (dec) O~S~O
N
N
O
O O

CI
N
N \ ~ ~>--H CI
'N
86 HN N CHs 240-241 I H
(dec) CI
N
HsC'N \ ~ ~ H CI
~'N
I
87 ~N O CHs 126-128 H

CI
N
HsC'N \ ~ >-- H CI
~N
88 ' \ N O CHs 228-230 H
CI
N
H~N~H N \ ~ ~N CI
I _N H
89 ~ ~ N O CHs 197-205 CHs H

CI
N
\ ~ ~H CI
N N
90 I \ N O CH3 215 H
O;SvO
N
N

HN
CI
N
\ I ~H CI
N N
91 I \ N O CH3 >300 H
O~S~ O
N
N

OH
CI
N
N'H N \ ~ ~N CI
H
92 HEN \ \ N O CH3 >300 H ~ / CH3 H

CI
N
N \ ~ >--H CI
I 'N
93 ~ N O CH3 >300 H
CI
N
\ ~ ~H CI
N N

94 O / ~H O CH3 210-215 ~N
HsC IO

CI
N
\ ~ >-H CI
N N
I v 95 l ~H O CH3 265 (dec) HN

CI
N
CI
N N
96 O I \ N O CH3 190 O~S H
I
N
N
O' _O
I 'CH3 H3C~CHs CI
N
N \ ~ ~N Cl N02 I 'N H
g7 ~ ~ ~~~N O CH3 315-317 / CH3 H (dec) CI
N
\ ~ >--H CI
N N
93 S ~ N O CH3 290 (dec) ~N H
H
NH

CI
N
H N \ I ~N CI
H
99 HEN '~ ~ ' CH 195-200 ~ N O s / CH3 H (dec) H~N~H
CI
N
CI
N N
100 p I \ N p CH3 246 H
i I
N
N
H
CI \
N
CI
N
~N
101 ~ ~ ~~~N CH3 170 (dec) / CH3 H p NH
HN ~H~

CI
N
N
II N \ I ~N CI
H
102 ~ ~ ~~ ~N CH3 . 284-288 H C CHs O HO'~C CH3 CI
N
H3C O N~ NH CH3 I N CI
\ N H
103 O HN ~- ~ N H >300 O ~ / CH3 H O
HsC O
N ~ NH
HsC~CH

O'\ /NH
H3C ~O
I _CH3 CI
N
HN NH2 N \ I >--N CI
H
HN ~ ~ H

N O

HN\ /NH

Assessment of Biological Properties Tyrosine Kinase Inhibition Assay The inhibition of tyrosine kinases by the compounds of the invention was measured with the following assay.
Kinase Reaction Buffer 50mM Hepes, pH 7.5, 50mM KCI, 25mM MgCl2, SmM MnCla, l0 100 ~M, Na3V04, .O1% CHAPS, 1mM DTT, and 50mg/mL BSA, Adenosine 5'-Triphosphate (ATP) solution at 100mM, pH 7.5 -y33P-ATP, 2000 Ci/mmol at 10~.Ci/~l, -Poly(L-glutamic acid-L-tyrosine, 4:1) or (E4Y)" at lOmg/mL in water.
Assay: Test compounds, obtained routinely at Smg/mL in 100% DMSO were diluted 15 appropriately into complete Kinase assay buffer with 10% DMSO, 10,1 of the compound solution was distributed into each assay well, the final compound concentration for ICso determinations ranged from 200 to l~g/mL. [y33P]-ATP label was prepared as a Cilmmol working solution in complete Kinase assay buffer. Protein kinase was initiated by adding 10 to 50r~g of diluted enzyme stock.
Plates were incubated at 30 °C for 30 min. During the incubation period, the MultiScreen harvest plates were pre-wetted with 10% TCA/5% Ppi. 1501 of TCA/PPi was added to all MultiScreen plate wells after pre-wetting. The kinase reaction was stopped via replica transfer of the polypropylene reaction wells into the MultiScreen plates. The plates were incubated at room temperature for 5 min then vacuum harvested and washed with 200 ~,l TCA/PPi 3-4 times per well, then 100 ~,1 of cocktail per well was added.
Experimental data consisted of eight (8) compound doses in duplicate with ten (10) enzyme control reaction wells (so-called totals) and six (6) background wells.
The results are presented as Percent Inhibition (Mean with S.D.) over the full compound dose range.
ICSO potency estimates are determined using a floating inhibition maximum (Imax).
All compounds in the synthetic examples and Tables above were evaluated in the tyrosine kinase assay above using p56 lck and were found to have ICSO's less than 10 p,M.
Representative compounds from the examples above were evaluated in the tyrosine kinase assay above using p60 src and were found to have ICSO's less than 10 p.M.
1o Representative compounds from the examples above were evaluated in the tyrosine kinase assay above using PDGFR kinase and were found to have ICso's less than 10 ~M.
Inhibition of IL-2 Production 15 Inactivation of T cells resulting from inhibition of the tyrosine kinase p56 lck can be measured by inhibition of IL-2 production in Jurkat cells. 96-well flat bottom plates were coated with anti-CD3, clone UCHT1, (Immunotech cat. # 1304) at 4 ~.g/ml in Phosphate Buffered Saline (PBS), 100 wlfwell. The solution was prepared by taking 200 p1 of 200 wg/ml anti-CD3 stockl lOml PBS. The plate was then incubated at 37°C
for 2h. Jurkat 20 cells were pelleted and counted. The cells were resuspended at 2.5 x 10 6 cells/ml in RPMI, 10 % FBS (complete media). Test compounds were diluted from a Smg/ml DMSO
stock directly into complete media.
p1 of 20 X compound/ well was added to a separate plate, followed by 100p,1 of cell suspension in triplicate and this plate was preincubated at 37°C for 30min. The 96-well 25 plate containing anti-CD3 was aspirated, and the cells and compound transferred to this plate. 100 p1 of PMA (Phorbol 12-Myristate 13-Acetate, Sigma cat.# P-8139) at 20 ng/ml was added, and the plate was incubated overnight at 37° C. (PMA stock at 1 mg/ml in ethanol, dilute 10 p,llml in complete media, then 20 X1110 mls. in complete media. 100 ~,1/well = 10 nglml. final concentration). The next day, the plate was centrifuged at 1500 30 rpm for 5 min. at room temperature and the supernatants were removed. The supernatants were tested using R&D Systems Quantikine Human IL-2 Kit (cat.#2050). Samples were diluted 1:5 in RPMI1640, and 100 ~.1/well used in the ELISA. The optical density of each well was determined using a microplate reader set to 450 nm. ECso values were determined using Origin (non-linear regression) or SAS by plotting absorbance vs.
concentration of compound.
Representatives from the synthetic examples and the Tables above were screened in this assay and had ICSO's below 10 ~M.

Claims (122)

We claim:

1. A compound of the following formula (I):
wherein:

Ar1 is an aromatic or nonaromatic carbocycle, heteroaryl or heterocycle;
wherein said carbocycle, heteroaryl or heterocycle is optionally substituted by one or more R1, R2 and R3;

X is NH, N-C1-3alkyl, N-cyclopropyl, S or O;
Y is NR13;

R1 and R2 are the same or different and are selected from H, halogen, CN, NO2, branched or unbranched saturated or unsaturated alkyl, C1-10 branched or unbranched alkoxy, C1-10 branched or unbranched acyl, C1-10 branched or unbranched acyloxy, C1-10 branched or unbranched alkylthio, aminosulfonyl, di-(C1-3)alkylaminosulfonyl, NR8R9, aryl, aroyl, aryloxy, arylsulfonyl, heteroaryl and heteroaryloxy; wherein the abovementioned R1 and R2 are optionally partially or fully halogenated or optionally substituted with one to three groups independently selected from the group consisting of oxo, OH, NR8R9, C1-6 branched or unbranched alkyl, C3-7cycloalkyl, phenyl, naphthyl, heteroaryl, aminocarbonyl and mono- or di(C1-3)alkylaminocarbonyl;

R3 is selected from the group consisting of H, halogen, OH, (CH2)n NR8R9, (CH2)n CO2R10, C1-3alkyl optionally substituted with OH, C1-3 alkoxy optionally halogenated and C1-3 alkylthio;

Het represents a fused heterocyclic ring having a formula A, B or C:
R4 is selected from H, C1-6 alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with phenyl, OH or C1-3alkoxy, C3-10-cycloalkyl, and C5-8cycloalkenyl;
or R4 is selected from (CH2)m,NR8R9, (CH2)m NR8COR10, (CH2)n CO2R10, (CH2)n CONR8R9, phenyl, heteroaryl and heterocycle, each phenyl, heteroaryl or heterocycle being optionally substituted with C1-3alkyl, C1-3alkoxy, (CH2)m NR8R9, OH, SO3H or halogen;

R5 is selected from H, C1-10alkyl branched or unbranched, C3-10 cycloalkyl, C5-7cycloalkenyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6acyl, each being optionally substituted with one or more halogen, OH, oxo, CN, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-3alkoxy, NR8R9, ureido, guanidino, NR8COR10, SR10, CONR8R9, CO2R10, C3-10 cycloalkyl, C3-10cycloalkylidene, C5-7cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle;
wherein each of C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10cycloalkyl, C3-10cycloalkylidene, C5-7cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle is optionally substituted with one or more C1-3alkyl, C1-3alkoxy, halogen, CN, NO2, amidino, guanidino, (CH2)n NR8R9, or O(CH2)2-4NR8R9; wherein one or more of the amino nitrogens in the ureido, amidino or guanidino groups in this paragraph may be optionally substituted with C1-3alkyl, phenylC0-3alkyl, C1-3alkoxy or CO2R10;

or R5 is selected from CO2R10, NR8R9, CONR8R9, aryl, heteroaryl, heterocycle, aryl-CO-, heteroaryl-CO- and heterocycle-CO-, wherein each aryl, heteroaryl or heterocycle is optionally substituted with one to three:

C1-3alkoxy, halogen, NO2, CN, S(O)p NR8R9, C0-3alkylS(O)p, NR8R9, (CH2)nCO2R10, (CH2)n CONR8R9, CO(CH2)n NR8R9, O(CH2)2-4NR8R9, ureido, guanidino, cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkyl-Z-, aryl-Z-, heteroaryl-Z-, heterocycle-Z-, or C1-3alkyl optionally substituted with phenyl or NR8R9, wherein Z is a bridging group selected from C1-10 alkylene branched or unbranched, CO, S(O)p, O, S, NH, CONH, NHCO, COO
and OOC, and wherein each cycloalkyl, aryl, heteroaryl or heterocycle is optionally substituted with NO2, C1-3alkyl, C1-3alkoxy, halogen, CO2R10, (CH2)2-4NR8R9, O(CH2)2-4NR8R9, ureido or guanidino, wherein one or more of the amino nitrogens in the ureido or guanidino groups in this paragraph may be optionally substituted with C1-3alkyl, phenylC0-3alkyl or C1-3alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;

or R5 is a C6-12 bridged- or spiro-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 3 carbon atoms in the ring system may be replaced by heteroatoms selected from N, O and S; and wherein said ring system may be optionally substituted with C1-3alkyl, C1-3alkoxy, halogen, C02R10, ureido, guanidino, amidino, (CH2)n NR8R9, or O(CH2)2-4NR8R9; wherein one or more of the amino nitrogens in the ureido, guanidino or amidino groups in this paragraph may be optionally substituted with C1-3alkyl, phenylCO-3alkyl or C1-3alkoxy;

R6 is selected from H, C1-6alkyl branched or unbranched, C2-6 alkenyl branched or unbranched, C02R10, C3-8cycloalkyl, C3-8cycloalkenyl, aryl, arylC1-3alkyl, heteroaryl and heterocyclyl; wherein said C1-6alkyl, C2-6alkenyl, C3-scycloalkyl, C3-8cycloalkenyl, aryl, arylC1-3alkyl, heteroaryl or heterocyclyl are optionally substituted with OH, C1-3alkoxy, C1-3acyloxy, C02R10, NR11R12, O(CH2)2-4NR11R12, aryl, heteroaryl or heterocyclyl;

R7 is H or C1-6alkyl;

R8 and R9 are the same or different and are each independently selected from H, OH, CO2R10, C1-10 acyl branched or unbranched, C1-3alkoxy, C1-6alkyl branched or unbranched, C3-6alkenyl,C3-8cycloalkyl, aryl, arylC1-3alkyl, aroyl, heteroaryl and heterocycle; wherein said alkyl, cycloalkyl, aryl, arylC1-3alkyl, aroyl, heteroaryl and heterocycle are optionally substituted with OH, C1-3alkoxy, C1-3acyloxy, C02R10, NR11R12, O(CH2)2-4NR11R12, aryl or heteroaryl;

or R8 and R9 together form a 3-7 member alkylene chain completing a ring about the N
atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, S(O)p, NCOR10, NCO2R10, NR11 or NC(=NR11)NR11R12; and wherein said ring is optionally substituted by C1-3 alkyl, C1-3alkoxy, OH or -(CH2)n NR11R12;

R10 is selected from H, C1-6alkyl, and C3-8cycloalkyl, wherein each aIkyl or cycloalkyl is optionally substituted with phenyl, OH, C1-3alkoxy, C1-3alkanoyloxy or NR11R12, or R10 is phenyl optionally substituted with one to three C1-3alkyl, C1-3alkoxy, halogen, (CH2)m NR8R9, (CH2)n CONR8R9 or O(CH2)24NR8R9;

R11 and R12 are each independently selected from H and C1-6 alkyl optionally substituted with C1-3alkoxy, OH or phenyl;
or R11 and R12 together form a chain completing a ring, said chain is (CH2)4-5 or.
(CH2)2O(CH2)2;

R13 is H or C1-3alkyl;

P and Q are each independently CH or N;
m is 1-4;

n is 0-3;
and p is 0-2;

wherein one or more of the primary amine or secondary amine nitrogen atoms in any of the R4, R5, R6 and R7 substituent groups may optionally be protected by a protecting group;

or a pharmaceutically acceptable derivative thereof.

2. A compound or derivative according to claim 1 wherein:
Ar1 is a) a cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl and cycloheptanyl;
b) a cycloalkenyl group selected from cyclopentenyl, cyclohexenyl, and cycloheptenyl;
c) an aromatic carbocycle selected from phenyl, naphthyl, indanyl, indenyl, dihydronaphthyl, tetrahydronaphthyl or fluorenyl, d) a heteroaryl selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl, benzothiazolyl, quinazolinyl, and indazolyl,or a fused heteroaryl selected from cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline, cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline, cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole, cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole, cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and cyclohexanothiophene; or e) a heterocycle selected from: pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl and indolinyl;

wherein each of the above Ar1 are optionally substituted by one or more R1, R2 and R3;
R1 and R2 are as defined in claim 1, and R3 is H, halogen, methyl, methoxy, hydroxymethyl or OH;

R4 is H, C1-3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)2-3NR8R9, (CH2)n CO2R10 or (CH2)n CONR8R9;
R5 is selected from H, C1-10alkyl branched or unbranched, C3-10 cycloalkyl, C5-7cycloalkenyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6acyl, each being optionally substituted with one or more halogen, OH, oxo, CN, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-3alkoxy, NR8R9, ureido, guanidino, NR8COR10, SR10, CONR8R9, C02R10, C3-10 cycloalkyl, 10cycloalkylidene, C5-7cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle;
wherein each of C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10cycloalkyl, C3-10cycloalkylidene, C5-7cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle is optionally substituted with one or more C1-3alkyl, C1-3alkoxy, halogen, CN, NO2, amidino, guanidino, (CH2)n NR8R9, or O(CH2)2-4NR8R9; wherein one or more of the amino nitrogens in the ureido, amidino or guanidino groups in this paragraph may be optionally substituted with C1-3alkyl, phenylC0-3alkyl, C1-3alkoxy or C02R10;

or R5 is selected from C02R10, NR8R9, CONR8R9, aryl, heteroaryl, heterocycle, aryl-CO-, heteroaryl-CO- and heterocycle-CO-, wherein each aryl, heteroaryl or heterocycle is optionally substituted with one to three:

C1-3alkoxy, halogen, NO2, CN, S(O)p NR8R9, C0-3alkylS(O)p, NR8R9, (CH2)n CO2R10, (CH2)n CONR8R9, CO(CH2)n NR8R9, O(CH2)2-4NR8R9, ureido, guanidino, cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkyl-Z-, aryl-Z-, heteroaryl-Z-, heterocycle-Z-, or C1-3alkyl optionally substituted with phenyl or NR8R9, wherein Z is a bridging group selected from C1-10 alkylene branched or unbranched, CO, S(O)p, O, S, NH, CONH, NHCO, COO
and OOC, and wherein each cycloalkyl, aryl, heteroaryl or heterocycle is optionally substituted with NO2, C1-3alkyl, C1-3alkoxy, halogen, CO2R10, (CH2)n NR8R9, O(CH2)2-4NR8R9, ureido or guanidino, wherein one or more of the amino nitrogens in the ureido or guanidino groups in this paragraph may be optionally substituted with C1-3alkyl, phenylC0-3alkyl or C1-3allkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;

or R5 is a C6-12 bridged- or spiro-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 3 carbon atoms in the ring system may be replaced by heteroatoms selected from N, O and S; and wherein said ring system may be optionally substituted with C1-3alkyl, C1-3alkoxy, halogen, CO2R10, ureido, guanidino, amidino, (CH2)n NR8R9, or O(CH2)2-4NR8R9; wherein one or more of the amino nitrogens in the ureido, guanidino or amidino groups in this paragraph may be optionally substituted with C1-3alkyl, phenylC0-3alkyl or C1-3alkoxy;

R6 is selected from H, C1-6alkyl branched or unbranched, C2-6 alkenyl branched or unbranched, and CO2R10; wherein said C1-6alkyl or C1-6 alkenyl are optionally substituted with OH, C1-3alkoxy, C2-3acyloxy, CO2R10, NR11R12, O(CH2)2-4NR11R12, aryl, heteroaryl or heterocyclyl;

R7 is H or C1-6alkyl;

R8 and R9 are the same or different and are each independently selected from H, OH, C1-3alkyl branched or unbranched, CO2R10, C3-8cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl and heterocycle; wherein said alkyl, cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl and heterocycle are optionally substituted with OH, C1-3alkoxy, C1-3acyloxy, CO2R10, NR11R12, O(CH2)2-4NR11R12, aryl or heteroaryl;

or R8 and R9 together form a 3-7 member alkylene chain completing a ring about the N
atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, S(O)p, NCOR10, NCO2R10, NR11 or NC(=NR11)NR11R12; and wherein said ring is optionally substituted by C1-3 alkyl, C1-3alkoxy, OH or -(CH2)n NR11R12;

R10 is H or C1-6alkyl optionally substituted with phenyl, OH, C1-3alkoxy, C1-3alkanoyloxy or NR11R12;

R11 and R12 are each independently selected from H and C1-6 alkyl optionally substituted with C1-3alkoxy, OH or phenyl;

or R11 and R12 together form a chain completing a ring, said chain is (CH2)4-5 or (CH2)2O(CH2)2;

R13 is H; and P and Q are each CH.

3. A compound or derivative according to claim 2 wherein:

Ar1 is phenyl or pyridyl, each optionally substituted by one or more R1, R2 and R3;
X is NH or N-C1-3alkyl;

Y is NH;
R1 and R2 are the same or different and selected from: halogen; C1-3 alkyl, wherein the C1-3 alkyl is optionally partially or fully halogenated, NO2 and NR8R9;

R3 is H, halogen, methyl or methoxy;

R4 is H, C1-3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)2-3NR8R9 or CO2R10;

R5 is selected from H, C1-3alky1 branched or unbranched, C3-8 cycloalkyl, C5-7cycloalkenyl and C2-4 alkenyl, each being optionally substituted with one or more OH, CN, NR8R9, CONR8R9, C3-8 cycloalkyl, C5-7cycloalkenyl, phenyl, heteroaryl or heterocycle; wherein each phenyl, heteroaryl or heterocycle is optionally substituted with one or more C1-3alkyl, C1-3alkoxy, halogen, CN, NO2, amidino, guanidino, (CH2)n NR8R9, or O(CH2)2-4NR8R9; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with C1-3alkyl, phenylC0-3alkyl, C1-3alkoxy or CO2R10;

or R5 is selected from CO2R10, NR8R9, CONR8R9, phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl, and indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl or indolyl-CO- is optionally substituted with one to three:

halogen, NO2, S(O)p NR8R9, C0-3alkylS(O)p, NR8R9, (CH2)n CO2R10, ureido, guanidino, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, phenyl-Z-, heteroaryl-Z-, heterocycle-Z-, or C1-3alkyl optionally substituted with phenyl or NR8R9, wherein Z is a bridging group selected from C1-3 alkylene branched or unbranched, O, S(O)p and NH, and wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO2, C1-3alkyl, C1-3alkoxy, CO2R10, (CH2)n NR8R9, O(CH2)2-4NR8R9 or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C1-3alkyl, phenylC0-3alkyl or C1-3alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;

or R5 is a C6-7 bridged-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 1 carbon atom in the ring system may be replaced by a nitrogen atom; and wherein said ring system may be optionally substituted with C1-3alkyl, C1-3alkoxy, halogen, (CH2)n NR8R9, or O(CH2)2-4NR8R9;

R6 is selected from H, C1-6alkyl branched or unbranched and CO2R10;
R7 is H or C1-6alkyl;

R8 and R9 are the same or different and are each independently selected from H, C1-3alkyl branched or unbranched, CO2R10, phenyl, and benzoyl; wherein said alkyl, phenyl and benzoyl are optionally substituted with OH or C1-3alkoxy;

or R8 and R9 together form a-(CH2)2-N(CO2R10)-(CH2)2- group, a-(CH2)2-N(COR10)-(CH2)2- group, a - (CH2)2-N(R11)-(CH2)2- group or a-(CH2)2-N(C(=NR11)NR11R12)-(CH2)2- group; and wherein said ring is optionally substituted by C1-3 alkyl, C1-3alkoxy, or OH;

R10 is H or C1-6alkyl optionally substituted with phenyl, OH, C1-3alkoxy, C1-3alkanoyloxy or NR11R12;

R11 and R12 are each independently selected from H and C1-3 alkyl optionally substituted with C1-3alkoxy or OH;

or R11 and R12 together form a chain completing a ring, said chain is (CH2)4-5 or (CH2)2O(CH2)2.

4. A compound or derivative according to claim 3 wherein:
Ar1 is phenyl;

R1 and R2 are the same or different and selected from: halogen, methyl optionally partially or fully halogenated, NO2 and NH2;

R3 is H, chloro, fluoro, bromo or methoxy;

R5 is selected from C2-4 alkenyl, C3-8 cycloalkyl and C5-7cycloalkenyl, each being optionally substituted with one or more OH, CN, NR8R9, CONR8R9 or phenyl;
wherein phenyl is optionally substituted with one or more C1-3alkyl, C1-3alkoxy, halogen, amidino, guanidino, (CH2)n NR8R9, or O(CH2)2-4NR8R9; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with C1-3alkyl, phenylC0-3alkyl or C1-3alkoxy;

or R5 is selected from phenyl, furyl, thienyl, oxazolyl, thiazolyl , pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl and indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl,1,2,5,6-tetrahydropyridinyl, pyrrolinyl,1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO- is optionally substituted with one to two:

halogen, NO2, SO2NR8R9, NR8R9, (CH2)n CO2R10, ureido, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, heteroaryl-Z- or heterocycle-Z-, or C1-3alkyl optionally substituted with NR8R9, wherein Z is a bridging group selected from alkylene branched or unbranched and S(O)p, wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO2, C1-3alkyl, CO2R10, NR8R9 or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C1-3alkyl; and wherein each alkyl and phenyl in this paragraph is optionally partially or fully halogenated;

or R5 is a 7-azabicyclo[2.2.1]heptane ring system, optionally having one or two double bonds in the ring system, wherein said ring system may be optionally substituted with C1-3alkyl, C1-3alkoxy, halogen, (CH2)n NR8R9, or O(CH2)2-4NR8R9;

R6 is selected from H and C1-3alkyl branched or unbranched, R7 is H or C1-3alkyl;

R8 and R9 are the same or different and are each independently selected from H
and C1-3alkyl branched or unbranched; wherein said alkyl is optionally substituted with OH or C1-3alkoxy;

or R8 and R9 together form a-(CH2)2-N(CO2R10)-(CH2)2- , a-(CH2)2-N(COR10)-(CH2)2- group, a-(CH2)2-N(R11)-(CH2)2- group or a-(CH2)2-N(C(=NR11)NR11R12)-(CH2)2- group; and wherein said ring is optionally substituted by C1-3 alkyl, C1-3alkoxy, or OH;

R10 is H or C1-3alkyl optionally substituted with phenyl, OH or C1-3alkanoyloxy;
and R11 is selected from H and C1-3 alkyl.

5. A compound or derivative according to any one of claims 1 to 4, wherein the Het represents a fused ring having formula B:

wherein R5 is as defined in any one of claims 1 to 4.

6. A compound according to claim 1, represented by the following formula (I'):

wherein R1, R2, R3, X, P, Q and Het are as defined in claim 1;
or a pharmaceutically acceptable derivative thereof.

7. A compound or derivative according to claim 6 wherein:
X is NH or N-C1-3alkyl;

R1 and R2 are the same or different and selected from: halogen, C1-3 alkyl, wherein the C1-3 alkyl is optionally partially or fully halogenated, NO2 and NR8R9;
R3 is H, halogen, methyl or methoxy;

R4 is H, C1-3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)2-3NR8R9 or CO2R10;

R5 is selected from H, C1-3alkyl branched or unbranched, C3-8 cycloalkyl, C5-7cycloalkenyl and C2-4 alkenyl, each being optionally substituted with one or more OH, CN, NR8R9, CONR8R9, C3-8 cycloalkyl, C5-7cycloalkenyl, phenyl, heteroaryl or heterocycle; wherein each phenyl, heteroaryl or heterocycle is optionally substituted with one or more C1-3alkyl, C1-3alkoxy, halogen, CN, NO2, amidino, guanidino, (CH2)n NR8R9, or O(CH2)2-4NR8R9; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with C1-3alkyl, phenylC0-3alkyl, C1-3alkoxy or CO2R10;

or R5 is selected from CO2R10, NR8R9, CONR8R9, phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl, and indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl or indolyl-CO- is optionally substituted with one to three:

halogen, NO2, S(O)p NR8R9, C0-3alkylS(O)p, NR8R9, (CH2)n CO2R10, ureido, guanidino, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, phenyl-Z-, heteroaryl-Z-, heterocycle-Z-, or C1-3alkyl optionally substituted with phenyl or NR8R9, wherein Z is a bridging group selected from C1-3 alkylene branched or unbranched, O, S(O)p and NH, and wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO2, C1-3alkyl, C1-3alkoxy, CO2R10, (CH2)n NR8R9, O(CH2)2-4NR8R9 or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with Cl-3alkyl, phenylC0-3alkyl or C1-3alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;

or R5 is a C6-7 bridged-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 1 carbon atom in the ring system may be replaced by a nitrogen atom; and wherein said ring system may be optionally substituted with C1-3alkyl, C1-3alkoxy, halogen, (CH2)n NR8R9, or O(CH2)2-4NR8R9;

R6 is selected from H, C1-6alkyl branched or unbranched and CO2R10;
R7 is H or C1-6alkyl;

R8 and R9 are the same or different and are each independently selected from H, C1-3alkyl branched or unbranched, CO2R10, phenyl, and benzoyl; wherein said alkyl, phenyl and benzoyl are optionally substituted with OH or C1-3alkoxy;

or R8 and R9 together form a - (CH2)2-N(CO2R10)-(CH2)2- group, a-(CH2)2-N(COR10)-(CH2)2- group, a-(CH2)2-N(R11)-(CH2)2- group or a-(CH2)2-N(C(=NR11)NR11R12)-(CH2)2- group; and wherein said ring is optionally substituted by C1-3 alkyl, C1-3alkoxy, or OH;

R10 is H or C1-6alkyl optionally substituted with phenyl, OH, C1-3alkoxy, C1-3alkanoyloxy or NR11R12;

R11 and R12 are each independently selected from H and C1-3 alkyl optionally substituted with C1-3alkoxy or OH;

or R11 and R12 together form a chain completing a ring, said chain is (CH2)4-5 or (CH2)2O(CH2)2; and P and Q are each CH,

8. A compound or derivative according to claim 7, wherein R1 and R2 are the same or different and selected from: halogen, methyl optionally partially or fully halogenated, NO2 and NH2;
R3 is H, chloro, fluoro, bromo or methoxy;

R5 is selected from C2-4 alkenyl, C3-8 cycloalkyl and C5-7cycloalkenyl, each being optionally substituted with one or more OH, CN, NR8R9, CONR8R9 or phenyl;
wherein phenyl is optionally substituted with one or more C1-3alkyl, C1-3alkoxy, halogen, amidino, guanidino, (CH2)n NR8R9, or O(CH2)2-4NR8R9; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with C1-3alkyl, phenylC0-3alkyl or C1-3alkoxy;

or R5 is selected from phenyl, furyl, thienyl, oxazolyl, thiazolyl , pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl and indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO- is optionally substituted with one to two:

halogen, NO2, SO2NR8R9, NR8R9, (CH2)n CO2R10, ureido, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, heteroaryl-Z- or heterocycle-Z-, or C1-3alkyl optionally substituted with NR8R9, wherein Z is a bridging group selected from Cl-3 alkylene branched or unbranched and S(O)p, wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO2, C1-3alkyl, CO2R10, NR8R9 or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C1-3alkyl; and wherein each alkyl and phenyl in this paragraph is optionally partially or fully halogenated;

or R5 is a 7-azabicyclo[2.2.1]heptane ring system, optionally having one or two double bonds in the ring system, wherein said ring system may be optionally substituted with C1-3alkyl, C1-3alkoxy, halogen, (CH2)n NR8R9, or O(CH2)2-4NR8R9;

R6 is selected from H and C1-3alkyl branched or unbranched;
R7 is H or C1-3alkyl;

R8 and R9 are the same or different and are each independently selected from H
and C1-3alkyl branched or unbranched; wherein said alkyl is optionally substituted with OH or C1-3alkoxy;

or R8 and R9 together form a-(CH2)2-N(CO2R10)-(CH2)2- , a-(CH2)2-N(COR10)-(CH2)2- group, a-(CH2)2-N(R11)-(CH2)2- group or a-(CH2)2-N(C(=NR11)NR11R12)-(CH2)2- group; and wherein said ring is optionally substituted by C1-3 alkyl, C1-3alkoxy, or OH;

R10 is H or C1-3alkyl optionally substituted with phenyl, OH or C1-3alkanoyloxy;
and R11 is selected from H and C1-3 alkyl.

9. A compound or derivative according to any one of claims 6 to 8, wherein the Het represents a fused ring having formula B:

wherein R5 is as defined in claim 6, 7 or 8.

10. A compound according to claim 1, represented by the following formula (Ib):
wherein R is H, C1-3alkyl or cyclopropyl, and Ar1 and R5 are as defined in claim 1;
or a pharmaceutically acceptable derivative thereof.

11. 2-(2,6-Dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

12. 2-(2,6-Dichlorophenylamino)-7-furan-2-yl-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

13. 2-(2,6-Dichlorophenylamino)-1-methyl-7-phenyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

14. 2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-nitrophenyl)-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

15. 7-(3-Aminophenyl)-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

16. 1-{3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-.function.]quinazolin-7-yl]-phenyl}-3-ethylurea; or a pharmaceutically acceptable derivative thereof.

17. 2-(2,6-Dichlorophenylamino)-1-methyl-7-vinyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

18. 2-(2,6-Dichlorophenylamino)-1-methyl-7-thiophen-2-yl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

19. 2-(2,6-Dichlorophenylamino)-1-methyl-7-[2-(3-nitrophenyl)-thiazol-4-yl]-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

20. 2-(2,6-Dichlorophenylamino)-7-imidazol-2-yl-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

21. 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-phenyloxazol-5-yl)-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

22. 2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-7-carboxamide; or a pharmaceutically acceptable derivative thereof.

23. 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-methylpropen-1-yl)-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

24. 2-(2,6-Dichlorophenylamino)-1-methyl-7-pyridin-2-yl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

25. 2-(2,6-Dichlorophenylamino)-1-methyl-7-pyridin-3-yl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

26. 2-(2,6-Dichlorophenylamino)-1-methyl-1H-imidazo[4,5-.function.]quinazoline-7,9-6H,8H-dione; or a pharmaceutically acceptable derivative thereof.

27. 2-(2,6-Dichlorophenylamino)-1-methyl-7-propen-2-yl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

28. 7-Cyclopent-1-enyl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

29. 7-[2-(3-Aminophenyl)-thiazol-4-yl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

30. Ethyl 2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-7-carboxylate; or a pharmaceutically acceptable derivative thereof.

31. 7-Benzofuran-2yl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

32. 2-(2,6-Dichlorophenylamino)-1-methyl-7-(1-methylprop-1-enyl)-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

33. 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-methyloxazol-5-yl)-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

34. 2-(2,6-Dichlorophenylamino)-7-(1H-indole-3-carbonyl)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

35. 2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-piperazin-1-yl-cyclopent-1-enyl)-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

36. 7-Cyclohex-1-enyl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

37. 2-(2,6-Dichlorophenylamino)-1-methyl-7-(1-methyl-1,2,5,6-tetrahydro-pyridin-3-yl)-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

38. 2-(2,6-Dichlorophenylamino)-1-methyl-7-[5-(2-nitrophenyl)-furan-2-yl]-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

39. 2-(2,6-Dichlorophenylamino)-7-furan-3-yl-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

40. 7-(5-Bromofuran-2-yl)-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

41. 2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-methylfuran-2-yl)-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

42. 7-Cyclopropyl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

43. 2-(2,6-Dichlorophenylamino)-1-methyl-7-[3-(4-methylpiperazine-1-sulfonyl)-phenyl]-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

44. 4-{3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-.function.]quinazolin-7-yl]-cyclopent-2-enyl}-piperazine-1-carboxylic acid tert-butyl ester; or a pharmaceutically acceptable derivative thereof.

45. 2-(2,6-Dichlorophenylamino)-7-(3-hydroxycyclopent-1-enyl)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

46. 2-(2,6-Dichlorophenylamino)-1-methyl-7-[3-(piperazine-1-sulfonyl)-phenyl]-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

47. 3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-.function.]quinazolin-7-yl]-cyclopent-3-enecarbonitrile; or a pharmaceutically acceptable derivative thereof.

48. 7-Amino-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

49. 3-{2-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-.function.]quinazolin-7-yl]-propenyl}-benzonitrile; or a pharmaceutically acceptable derivative thereof.

50. 3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-.function.]quinazolin-7-yl]-cyclopent-3-enecarboxamide; or a pharmaceutically acceptable derivative thereof.

51. 2-{4-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-.function.]quinazolin-7-yl]-thiazol-2-yl}-pyrrolidine-1-carboxylic acid benzyl ester; or a pharmaceutically acceptable derivative thereof.

52. 2-(2,6-Dichlorophenylamino)-1-methyl-7-[1-methyl-2-(3-nitrophenyl)-vinyl]-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

53. 3-{4-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-.function.]quinazolin-7-yl]-thiazol-2-ylmethyl}-piperidine-1-carboxylic acid benzyl ester; or a pharmaceutically acceptable derivative thereof.

54. 7-[2-(2-Aminocyclohexyl)-thiazol-4-yl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

55. 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-piperidin-3-ylmethyl-thiazol-4-yl)-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

56. 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-methylthiazol-4-yl)-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

57. 2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-oxocyclopent-1-enyl)-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

58. 3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-.function.]quinazolin-7-yl]-2,5-dihydro-pyrrole-1-carboxylic acid tert-butyl ester; or a pharmaceutically acceptable derivative thereof.

59. 7-[2-(3-Aminophenyl)-1-methylvinyl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

60. Acetic acid 2-(4-{3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-.function.]quinazolin-7-yl]-benzenesulfonyl}-piperazin-1-yl)-2-oxoethyl ester; or a pharmaceutically acceptable derivative thereof.

61. 2-(2,6-Dichlorophenylamino)-7-(2,5-dihydro-1H-pyrrol-3-yl)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

62. 7-[2-(3-Aminomethylphenyl)-1-methylvinyl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

63. 4-{3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-.function.]quinazolin-7-yl]-benzenesulfonyl}-piperazine-1-carboxamidine; or a pharmaceutically acceptable derivative thereof.

64. 2-(2,6-Dichlorophenylamino)-7-{3-[4-(2-hydroxyacetyl)-piperazine-1-sulfonyl]phenyl}-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

65. 3-{2-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-.function.]quinazolin-7-yl]-propenyl}-benzamidine; or a pharmaceutically acceptable derivative thereof.

66. 7-(7-Azabicyclo[2.2.l]hepta-2,5-dien-2-yl)-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

67. 5-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-.function.]quinazolin-7-yl]-3,3a,4,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylic acid tert-butyl ester; or a pharmaceutically acceptable derivative thereof.

68. 2-(2,6-Dichlorophenylamino)-7-(1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrol-5-yl)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

69. 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-pyrrolidin-2-yl-thiazol-4-yl)-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

70. 7-[2-(3,5-Diaminophenyl)-1-methylvinyl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

71. 2-(2,6-Dichlorophenylamino)-1-methyl-7-[4-(piperazine-1-sulfonyl)-phenyl]-1,8-dihydro-9H-imidazo[4,5-.function.]quinazoline-9-one; or a pharmaceutically acceptable derivative thereof.

72. A pharmaceutical composition comprising a compound or derivative according to any one of claims 1 to 71 and a pharmaceutically acceptable carrier or diluent.

73. A pharmaceutical composition according to claim 72 for treating an autoimmune disease, cancer or a cerebral ischemic condition in a patient in need of said treating.

74. A pharmaceutical composition according to claim 73, wherein the autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, psoriasis, graft versus host disease, systemic lupus erythematosus, insulin-dependent diabetes mellitus and asthma.

75. A pharmaceutical composition according to claim 73, wherein the cancer is selected from a src-dependent tumor and a PDGF-dependent tumor.

76. A pharmaceutical composition according to claim 75, wherein the src-dependent tumor is selected from mammary carcinoma, colon carcinoma, melanoma and sarcoma.

77. A pharmaceutical composition according to claim 75, wherein the PDGF-dependent tumor is selected from ovarian cancer, prostate cancer and glioblastoma.

78. A pharmaceutical composition according to claim 73, wherein the cerebral ischemic condition is stroke.

79. A pharmaceutical composition according to claim 72 for treating a disease selected from osteoporosis, Paget's disease, bone inflammation, and joint inflammation in a patient in need of such treating.

80. A pharmaceutical composition according to claim 72 for treating a disease selected from fibrotic diseases, restenosis and atherosclerosis in a patient in need of such treating.

81. A pharmaceutical composition according to claim 72 for enhancing or potentiating the effectiveness of radiation therapy in a patient undergoing radiation therapy.

82. A use of a compound or derivative according to any one of claims 1 to 71 in preparation of a pharmaceutical composition for treating an autoimmune disease, cancer or a cerebral ischemic condition in a patient in need of such treating.

83. A use according to claim 82, wherein the autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, psoriasis, graft versus host disease, systemic lupus erythematosus, insulin-dependent diabetes mellitus and asthma.

84. A use according to claim 82, wherein the cancer is selected from a src-dependent tumor and a PDGF-dependent tumor.

85. A use according to claim 84, wherein the src-dependent tumor is selected from mammary carcinoma, colon carcinoma, melanoma and sarcoma.

86. A use according to claim 84, wherein the PDGF-dependent tumor is selected from ovarian cancer, prostate cancer and glioblastoma.

87. A use according to claim 82, wherein the cerebral ischemic condition is stroke.

88. A use of a compound or derivative according to any one of claims 1 to 71 in preparation of a pharmaceutical composition for treating a disease selected from osteoporosis, Paget's disease, bone inflammation, and joint inflammation in a patient in need of such treating.

89. A use of a compound or derivative according to any one of claims 1 to 71 in preparation of a pharmaceutical composition for treating a disease selected from fibrotic diseases, restenosis and atherosclerosis in a patient in need of such treating.

90. A use of a compound or derivative according to any one of claims 1 to 71 in preparation of a pharmaceutical composition for enhancing or potentiating the effectiveness of radiation therapy in a patient undergoing radiation therapy.

91. A use of a compound or derivative according to any one of claims 1 to 71 for treating an autoimmune disease, cancer or a cerebral ischemic condition in a patient in need of such treating.

92. A use according to claim 91, wherein the autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, psoriasis, graft versus host disease, systemic lupus erythematosus, insulin-dependent diabetes mellitus and asthma.

93. A use according to claim 91, wherein the cancer is selected from a src-dependent tumor and a PDGF-dependent tumor.

94. A use according to claim 93, wherein the src-dependent tumor is selected from mammary carcinoma, colon carcinoma, melanoma and sarcoma.

95. A use according to claim 93, wherein the PDGF-dependent tumor is selected from ovarian cancer, prostate cancer and glioblastoma.

96. A use according to claim 91, wherein the cerebral ischemic condition is stroke.

97. A use of a compound or derivative according to any one of claims 1 to 71 for treating a disease selected from osteoporosis, Paget's disease, bone inflammation, and joint inflammation in a patient in need of such treating.

98. A use of a compound or derivative according to any one of claims 1 to 71 for treating a disease selected from fibrotic diseases, restenosis and atherosclerosis in a patient in need of such treating.

99. A use of a compound or derivative according to any one of claims 1 to 71 for enhancing or potentiating the effectiveness of radiation therapy in a patient undergoing radiation therapy.

100. A compound or derivative according to any one of claims 1 to 71 for treating an autoimmune disease, cancer or a cerebral ischemic condition in a patient in need of such treating.

101. A compound or derivative according to claim 100, wherein the autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, psoriasis, graft versus host disease, systemic lupus erythematosus, insulin-dependent diabetes mellitus and asthma.

102. A compound or derivative according to claim 100, wherein the cancer is selected from a src-dependent tumor and a PDGF-dependent tumor.

103. A compound or derivative according to claim 102, wherein the src-dependent tumor is selected from mammary carcinoma, colon carcinoma, melanoma and sarcoma.

104. A compound or derivative according to claim 102, wherein the PDGF-dependent tumor is selected from ovarian cancer, prostate cancer and glioblastoma.

105. A compound or derivative according to claim 100, wherein the cerebral ischemic condition is stroke.

106. A compound or derivative according to any one of claims 1 to 71 for treating a disease selected from osteoporosis, Paget's disease, bone inflammation, and joint inflammation in a patient in need of such treating.

107. A compound or derivative according to any one of claims 1 to 71 for treating a disease selected from fibrotic diseases, restenosis and atherosclerosis in a patient in need of such treating.

108. A compound or derivative according to any one of claims 1 to 71 for enhancing or potentiating the effectiveness of radiation therapy in a patient undergoing radiation therapy.

109. A compound of the following formula VI:
wherein:
R is H, C1-3alkyl or cyclopropyl;

R4 is selected from H and C1-6 alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with phenyl, OH or C1-3alkoxy; or R4 is selected from (CH2)m NR8R9, (CH2)m NR8COR10, (CH2)n CO2R10 and (CH2)n CONR8R9;

R8, R9, R10 and m are as defined in claim 1; and n is 1-3;

wherein one or more of the primary amine or secondary amine nitrogen atoms in the R4 substituent group may optionally be protected by a protecting group.

110. A compound according to claim 109, wherein R is H or C1-3alkyl; R4 is H, C1-3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)2-3NR8R9, (CH2)n CO2R10 or (CH2)n CONR8R9,

111. A compound of the following formula XII:
wherein:

R is H, C1-3alkyl or cyclopropyl; and R5 is as defined in claim 1.

112. A compound according to claim 24, wherein:
R is H or C1-3alkyl;

R5 is selected from H, C1-3alkyl branched or unbranched, C3-8 cycloalkyl, C5-7cycloalkenyl and C2-4 alkenyl, each being optionally substituted with one or more OH, CN, NR8R9, CONR8R9, C3-8 cycloalkyl, C5-7cycloalkenyl, phenyl, heteroaryl or heterocycle; wherein each phenyl, heteroaryl or heterocycle is optionally substituted with one or more C1-3alkyl, C1-3alkoxy, halogen, CN, NO2, amidino, guanidino, (CH2)n NR8R9, or O(CH2)2-4NR8R9; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with C1-3alkyl, phenylC0-3alkyl, C1-3alkoxy or CO2R10;

or R5 is selected from CO2R10, NR8R9, CONR8R9, phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl, and indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl or indolyl-CO- is optionally substituted with one to three:

halogen, NO2, S(O)p NR8R9, C0-3alkylS(O)p, NR8R9, (CH2)n CO2R10, ureido, guanidino, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, phenyl-Z-, heteroaryl-Z-, heterocycle-Z-, or C1-3alkyl optionally substituted with phenyl or NR8R9, wherein Z is a bridging group selected from C1-3 alkylene branched or unbranched, O, S(O)p and NH, and wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO2, C1-3alkyl, C1-3alkoxy, CO2R10, (CH2)n NR8R9, O(CH2)2-4NR8R9 or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C1-3alkyl, phenylC0-3alkyl or C1-3alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;

or R5 is a C6-7 bridged-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 1 carbon atom in the ring system may be replaced by a nitrogen atom; and wherein said ring system may be optionally substituted with C1-3alkyl, C1-3alkoxy, halogen, (CH2)n NR8R9, or O(CH2)2-4NR8R9.

113. A compound according to claim 111, wherein:

R5 is selected from C2-4 alkenyl, C3-8 cycloalkyl and C5-7cycloalkenyl, each being optionally substituted with one or more OH, CN, NR8R9, CONR8R9 or phenyl;
wherein phenyl is optionally substituted with one or more C1-3alkyl, C1-3alkoxy, halogen, amidino, guanidino, (CH2)n NR8R9, or O(CH2)2-4NR8R9; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with C1-3alkyl, phenylC0-3alkyl or C1-3alkoxy;

or R5 is selected from phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl and indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO- is optionally substituted with one to two:

halogen, NO2, SO2NR8R9, NR8R9, (CH2)n CO2R10, ureido, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, heteroaryl-Z- or heterocycle-Z-, or C1-3alkyl optionally substituted with NR8R9, wherein Z is a bridging group selected from alkylene branched or unbranched and S(O)p, wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO2, C1-3alkyl, CO2R10, NR8R9 or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C1-3alkyl; and wherein each alkyl and phenyl in this paragraph is optionally partially or fully halogenated;

or R5 is a 7-azabicyclo[2.2.1]heptane ring system, optionally having one or two double bonds in the ring system, wherein said ring system may be optionally substituted with C1-3alkyl, C1-3alkoxy, halogen, (CH2)n NR8R9, or O(CH2)2-4NR8R9,

114. A method of making a compound of the formula Ib below:
wherein R is H, C1-3alkyl or cyclopropyl, and Ar1 and R5 are as defined in claim 1, said method comprising:

(a) reacting the compound of formula XIX (wherein R4 is H) with an acid halide of the formula R5COX, wherein X is a halogen, or with an acid anhydride of the formula (R5CO)2O, or with an acid of the formula R5CO2H and a coupling reagent, in a suitable solvent in the presence of a suitable base to form a compound of formula (b) cyclizing the compound of formula XXI by treatment with a suitable base in a suitable solvent at about reflux temperature to form a compound of formula Ib:

115. A method of making a compound of the formula Ib below:
wherein R is H, C1-3alkyl or cyclopropyl, and Ar1 and R5 are as defined in claim 1, said method comprising:

(a) reacting the compound of formula XIX (wherein R4 is H) with an aldehyde of the formula R5CHO in the presence of an acid in a suitable solvent to form a compound of formula Id:

(b) oxidizing the compound of formula Id with a suitable oxidizing agent to form the compound of formula Ib:

116. A method of making a compound of the formula Ib below:

wherein R is H, C1-3alkyl or cyclopropyl, and Ar1 and R5 are as defined in claim 1, said method comprising:

(a) reacting the compound of formula XVIII (wherein R4 is H) with an acid halide of the formula R5COX, wherein X is a halogen, or with an acid anhydride of the formula (R5CO)2O, or with an acid of the formula R5CO2H and a coupling reagent, in a suitable solvent in the presence of a suitable base to form a compound of formula XX:

(b) hydrolyzing and cyclizing the compound of formula XX by treatment with a suitable base and a suitable oxidant in a suitable solvent to form the compound of formula Ib:

117. A compound of the following formula XVIII:

wherein:
Ar1 is as defined in claim 1;
R is H, C1-3alkyl or cyclopropyl; and R4 is as defined in claim 1.

118. A compound according to claim 117, wherein:

Ar1 is a) ~a cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl and cycloheptanyl;

b) ~a cycloalkenyl group selected from cyclopentenyl, cyclohexenyl, and cycloheptenyl;

c) ~an aromatic carbocycle selected from phenyl, naphthyl, indanyl, indenyl, dihydronaphthyl, tetrahydronaphthyl and fluorenyl, d) ~a heteroaryl selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl, benzothiazolyl, quinazolinyl, and indazolyl,or a fused heteroaryl selected from cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline, cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline, cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole, cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole, cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and cyclohexanothiophene;or e) ~a heterocycle selected from: pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl and indolinyl;

wherein each of the above Ar1 are optionally substituted by one or more R1, R2 and R3;

R1 and R2 are as defined in claim 1, and R3 is hydrogen, halogen, methyl, methoxy, hydroxymethyl or OH; and R4 is H, C1-3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)2-3NR8R9, (CH2)n CO2R10 or (CH2)n CONR8R9;

R8 and R9 are the same or different and are each independently selected from H, OH, C1-3alkyl branched or unbranched, CO2R10, C3-8cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl and heterocycle; wherein said alkyl, cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle are optionally substituted with OH, C1-3alkoxy, C1-3acyloxy, CO2R10, NR11R12, O(CH2)2-4NR11R12, aryl or heteroaryl;

or R8 and R9 together from a 4-6 member alkylene chain completing a ring about the N
atom to which they are attached; wherein said alkylene chain is optionally interrupted by NCO2R10 or NR11; and wherein said ring is optionally substituted by C1-3 alkyl, 'C1-3alkoxy, OH or -(CH2)n NR11R12;

R10 is H or C1-6alkyl optionally substituted with phenyl, OH, C1-3alkoxy or NR11R12;

R11 and R12 are each independently selected from H and C1-6 alkyl optionally substituted with C1-3alkoxy, OH or phenyl;

or R11 and R12 together form a chain completing a ring, said chain is (CH2)4-5 or (CH2)2O(CH2)2; and n is 0-3.

119. A compound according to claim 118, wherein:

Ar1 is phenyl or pyridyl, each optionally substituted by one or more R1, R2 and R3;

R is H or C1-3alkyl;

R1 and R2 are the same or different and selected from: halogen, C1-3 alkyl, wherein the C1-3 alkyl is optionally partially or fully halogenated, NO2 and NR8R9;

R3 is H, halogen, methyl or methoxy;

R4 is H, C1-3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)2-3NR8R9 or CO2R10;

R8 and R9 are the same or different and are each independently selected from H, C1-3alkyl branched or unbranched, CO2R10, phenyl, and benzoyl; wherein said alkyl, phenyl or benzoyl are optionally substituted with OH or C1-3alkoxy;

or R8 and R9 together form a - (CH2)2-N(CO2R10)-(CH2)2- group or a-(CH2)2-N(R11)-(CH2)2- group; and wherein said ring is optionally substituted by C1-3 alkyl, C1-3alkoxy, or OH;

R10 is H or C1-3alkyl optionally substituted with phenyl, OH, C1-3alkoxy or NR11R12;
R11 and R12 are each independently selected from H and C1-3 alkyl optionally substituted with C1-3alkoxy or OH;

or R11 and R12 together form a chain completing a ring, said chain is (CH2)4-;
or (CH2)2O(CH2)2.

120. A compound of the following formula XIX:

wherein:
Ar1 is as defined in claim 1;
R is H, C1-3alkyl or cyclopropyl; and R4 is as defined in claim 1.

121. A compound according to claim 120, wherein:

Ar1 is a) a cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl and cycloheptanyl;
b) a cycloalkenyl group selected from cyclopentenyl, cyclohexenyl, and cycloheptenyl;
c) an aromatic carbocycle selected from phenyl, naphthyl, indanyl, indenyl, dihydronaphthyl, tetrahydronaphthyl and fluorenyl, d) a heteroaryl selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl, benzothiazolyl, quinazolinyl, and indazolyl,or a fused heteroaryl selected from cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline, cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline, cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole, cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole, cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and cyclohexanothiophene; or e) a heterocycle selected from: pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl and indolinyl;

wherein each of the above Ar1 are optionally substituted by one or more R1, R2 and R3;
R1 and R2 are as defined in claim 1, and R3 is hydrogen, halogen, methyl, methoxy, hydroxymethyl or OH; and R4 is H, C1-3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)2-3NR8R9, (CH2)n CO2R10 or (CH2)n CONR8R9;

R8 and R9 are the same or different and are each independently selected from H, OH, C1-3alkyl branched or unbranched, CO2R10, C3-8cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl and heterocycle; wherein said alkyl, cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle are optionally substituted with OH, C1-3alkoxy, C1-3acyloxy, C02R10, NR11R12, O(CH2)2-4NR11R12, aryl or heteroaryl;

or R8 and R9 together form a 4-6 member alkylene chain completing a ring about the N
atom to which they are attached; wherein said alkylene chain is optionally interrupted by NCO2R10 or NR11; and wherein said ring is optionally substituted by C1-3 alkyl, C1-3alkoxy, OH or -(CH2)n NR11R12;

R10 is H or C1-6alkyl optionally substituted with phenyl, OH, C1-3alkoxy or NR11R12;

R11 and R12 are each independently selected from H and C1-6 alkyl optionally substituted with C1-3alkoxy, OH or phenyl;

or R11 and R12 together form a chain completing a ring, said chain is (CH2)4-5 or (CH2)2O(CH2)2; and n is 0-3.

122. A compound according to claim 121, wherein Ar1 is phenyl or pyridyl, each optionally substituted by one or more R1, R2 and R3;
R is H or C1-3alkyl;

R1 and R2 are the same or different and selected from: halogen, Cl-3 all-yl, wherein the C1-3 alkyl is optionally partially or fully halogenated, NO2 and NR8R9;

R3 is H, halogen, methyl or methoxy;

R4 is H, C1-3alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R4 is (CH2)2-3NR8R9 or CO2R10;
R8 and R9 are the same or different and are each independently selected from H, C1-3alkyl branched or unbranched, CO2R10, phenyl, and benzoyl; wherein said alkyl, phenyl or benzoyl are optionally substituted with OH or C1-3alkoxy;

or R8 and Ry together form a - (CH2)2-N(CO2R10)-(CH2)2- group or a - (CH2)2-N(R11)-(CH2)2- group; and wherein said ring is optionally substituted by C1.3 alkyl, C1-3alkoxy, or OH;

R10 is H or C1-3alkyl optionally substituted with phenyl, OH, C1-3alkoxy or NR11R12z;

R11 and R12 are each independently selected from H and C1-3 alkyl optionally substituted with C1-3alkoxy or OH;

or R11 and R12 together form a chain completing a ring, said chain is (CH2)4-5 or (CH2)2O(CH2)2.